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Abstract 
 
 
 Mammalian nucleoside transporters can be classified into two main categories, 
namely, equilibrative nucleoside transporters (ENTs) and concentrative nucleoside 
transporters (CNTs). ENTs are ubiquitous, and mediate sodium-independent bi-
directional facilitated diffusion nucleoside transport processes. CNTs on the other hand, 
are secondary active unidirectional transporters that are sodium-dependent. Both the 
equilibrative and the concentrative nucleoside transporters have several family members 
which are ENT1 to ENT4 and CNT1 to CNT6. Over the past two decades, important 
advances in the understanding of nucleoside transporter functions have been made. 
Identification and molecular cloning of the ENT and CNT families from mammals and 
protozoan parasites have provided much information about the structure, function, 
regulation, and tissue and cellular localization. Structure–function analyses of various 
nucleoside transporter chimeras and mutants have revealed important elements involved 
in substrate and inhibitor recognition and binding. However, the mechanisms that 
regulate nucleoside transporters in various tissues and cell types are just beginning to be 
understood. Because of the ability of these transporters to handle nucleoside analogues 
used in the treatment of patients with cancer and viral diseases, ongoing research should 
allow the design of more specifically targeted new compounds or improvements to 
existing drugs. New drugs are welcome not only in the treatment of cancer and viral 
diseases, but also in cardiovascular disorders and parasitic infections.  
 
 Due to the absence of crystal structures and limited information regarding the 
active sites of nucleoside transporters, the designing of novel inhibitors is confined to 
ligand-based methods. In an effort to search for novel classes of inhibitors other than the 
existing ones, a series of 95 different flavone and flavone-like compounds was screened 
against concentrative nucleoside transporters (CNT 1, 2 and 3) and equilibrative 
nucleoside transporters (ENT 1 and 2). The results obtained in the form of IC50 values 
were further utilized to perform quantitative structure–activity relationship studies which 
indeed helped to understand the effects of different functionalities in the inhibition of 
nucleoside transporters. The validated 3D-QSAR models were used for design and 
activity prediction of new compounds. Pharmacophore hypotheses were also generated 
for hCNT3 using the PHASE pharmacophore mapping program to establish structural 
criteria for inhibitor design, and for database searching to find new hit molecules. 
Additionally, fifteen compounds were selected based on SAR and screened for 
equilibrative nucleoside transporter inhibition for validation of QSAR models. One novel 
compound, XI was designed with reduced complexity in further attempts to identify the 
ENT pharmacophore. But the synthetic route followed to prepare compound XI, resulted 
in the synthesis of compounds XII and XIII, which were evaluated as a mixture and 
exhibited substantial inhibitory activity against hENT1, but had no significant effect on 
hENT2 or hCNT3. 
 
This work has identified a novel class of CNT and ENT nucleoside transporter 
inhibitors and delineated structural determinants of potency and transporter subtype 
selectivity. 
 vi
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Chapter 1: Human Nucleoside Transporters 
 
 
1.1  Nucleoside Transporters 
 
Naturally occuring human nucleosides are glycosylamines containing a purine or 
a pyrimidine nitrogenous base attached to a ribose or a deoxyribose ring. The major 
physiological nucleosides commonly found in living organisms include cytidine, 
deoxycytidine, thymidine, and uridine obtained from a pyrimidine nitrogenous base and 
adenosine, deoxyadenosine, guanosine, deoxyguanosine and inosine obtained from a 
purine nucleobase (Figure 1.1). 
 
Nucleosides and nucleoside analogs can modulate a variety of biochemical and 
physiological processes. For example, adenosine is known to exert protective 
cardiovascular effects that make it clinically useful in the treatment of supraventricular 
tachycardia.1 Extracellularly, adenosine acts as a signaling molecule affecting a variety of 
physiological processes such as neurotransmission,2 platelet aggregation,3 vasodilation,4 
and lipolysis.5 The 5’-triphosphate nucleotide of adenosine, ATP, is largely responsible 
for meeting the energy demand in human tissues and acts as the energy currency of the 
cell, providing energy for a number of different cellular functions.6 Nucleotides such as 
cAMP also play an important role in a myriad of signal transduction processes.7 
Nucleotides containing ribose or deoxyribose serve as precursors for the biosynthesis of 
ribonucleic acid (RNA) or deoxyribonucleic acid (DNA), respectively.8, 9 However, 
physiological nucleosides are hydrophilic in nature and hence require assistance to cross 
hydrophobic cell membranes; and this is provided by nucleoside transporters.  
 
Nucleoside analogs commonly used as anticancer10 and antiviral agents,11 also 
need to be transported into cells to exert their effects, and nucleoside transporters are 
responsible for their uptake. Representative examples of nucleoside analogs include the 
anti-viral agents AZT (1-[4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-pyrimidine-
2,4-dione) and Idoxuridine (1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-
iodo-pyrimidin e-2,4-dione) and  the anticancer agents Ara-C (4-amino-1-
[(2R,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one) and 
Cladribine ((2R,3S,5R)-5-(6-amino-2-chloro-purin-9-yl)-2-(hydroxymethyl)oxolan- 
3-ol) (Figure 1.2). Nucleoside transporters are thus integral membrane glycoproteins that 
modulate the cellular uptake of physiological nucleosides and their synthetic analogs.12 
Nucleoside transporter-mediated cellular uptake of nucleosides by mammalian cells was 
first recognized in Ehrlich cells in 1962.13 The different isoforms of nucleoside 
transporters were not recognized until the early 1980’s. 14, 15 In humans, four equilibrative 
nucleoside transporters and six concentrative nucleoside transporters have been identified 
as shown in Figure 1.3. This classification has been discussed in detail later in this 
chapter. Figure 1.4 shows a model of nucleoside transport mediated by concentrative or 
equilibrative nucleoside transporter.  
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Figure 1.1:  Structures of physiological nucleosides 
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Figure 1.2:  Structures of representative antiviral and anticancer nucleoside analogs 
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Nucleoside Transporters 
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Figure 1.3:  Classification of human nucleoside transporters 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4:  Nucleoside transport mediated by Na+-dependent (CNT) and 
                              Na+-independent (ENT) nucleoside transporters 
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Nu 
Nu Nu 
Nu 
Nu Na+ 
EXTRACELLULAR 
INTRACELLULAR CNT ENT 
es ei 
NBMPR 
 5
1.2  Concentrative Nucleoside Transporters 
 
Concentrative nucleoside transporters (CNT) belong to the SLC28 family of 
proteins.16 Concentrative nucleoside transport processes are high-affinity, sodium-
dependent systems that mediate active uphill transport of nucleosides.17-19 Six 
concentrative nucleoside transporters have been identified but only three isoforms, CNT1 
(SLC28A1), CNT2 (SLC28A2, also termed SPNT) and CNT3 (SLC28A3) have been 
cloned. The three cloned CNTs have been predicted to be 13 TM domain proteins with 
the substrate translocation pore formed by TM domains 7 to 9 (Topographical model for 
CNT is shown in Figure 1.5).20  
 
The six concentrative nucleoside transporters are classified on the basis of their 
substrate specificities and inhibitor sensitivity as follows: 
 
N1/CNT2/cif (insensitive to NBMPR and accepts formycin as a substrate)21, 22 
N2/CNT1/cit (insensitive to NBMPR and accepts thymidine as a substrate)20  
N3/CNT3/cib (insensitive to NBMPR and exhibits broad substrate specificity)23  
N4/cit (like CNT2 but also accepts guanosine as a permeant) 
N5/cs (sensitive to NBMPR)  
N6/csg (sensitive to NBMPR and accepts guanosine as a substrate) 
 
 
1.2.1  Molecular Characteristics 
 
CNT1 was the first member of the concentrative nucleoside transporter family to 
be cloned. The rat CNT1 subtype, rCNT1, was the first to be functionally expressed in 
Xenopus laevis oocytes following isolation from rat jejunum.24 The human CNT1 
transporter (hCNT1) was cloned from kidney tissue using hybridization and reverse 
transcriptase polymerase chain reaction (RT-PCR) techniques.25 The hCNT1 nucleoside 
transporter encodes a protein containing 650 amino acid residues. The substrate and 
cation recognition sites are both located in the carboxy terminal half of the protein.25The 
rat CNT2 isoform, rCNT2, was first isolated from rat liver and functionally expressed in 
Xenopus laevis oocytes.21 The cloning of the human ortholog of CNT2, termed SPNT1 or 
hCNT2, was done using kidney cells.22 The hCNT2 protein has 658 amino acid residues 
and is predicted to consist of 13 TM domains. The hCNT2 protein is 72 % identical to the 
hCNT1 protein. Human CNT3, hCNT3, was first cloned from the human mammary 
gland and differentiated human myeloid HL-60 cells.23 The mouse ortholog, mCNT3 has 
also been cloned and characterized from mouse liver cells. The human and the mouse 
CNT3 are 78 % identical at the protein level. The hCNT3 gene encodes a 691 amino acid 
protein. The amino acid sequence of CNT3 is 48 % identical to CNT1 and 47 % identical 
to CNT2. As in the case of the other members of the CNT family, hCNT3 and mCNT3 
are predicted to have 13 TM domains.  
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Figure 1.5:  Topographical model of concentrative nucleoside transporter 
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1.2.2  Tissue Distribution 
 
In humans, hCNT1 is predominantly expressed in kidney and liver epithelial 
tissues26-28, with much lower expression in other tissues.29 Even within the kidney, there 
appears to be large inter-individual differences in hCNT1 mRNA expression.  In the 
epithelia, CNT1 is localized to the apical membrane and works along with equilibrative 
nucleoside transporters, which are localized predominantly in the baso-lateral membranes 
of these tissues, to mediate trans-epithelial nucleoside flux.27 Human CNT2 has a wider 
tissue distribution than hCNT1. It is widely distributed in the kidney, liver, heart, brain, 
placenta, pancreas, skeletal muscle, colon, rectum, duodenum, jejunum and ileum. 
hCNT2 is also expressed in normal human leukocytes and a number of neoplastic tissues 
and cancer cell lines. The distribution pattern of hCNT3 has been studied using an RNA 
array of 76 human tissues and cell lines.23 High levels of human CNT3 mRNA transcripts 
are found in the pancreas, trachea, bone marrow and mammary glands, whereas lower 
levels are found in the intestine, lung, placenta, prostrate, testis, kidney and liver. 
 
 
1.2.3  Transport of Physiological Nucleosides and Nucleoside Analogs 
 
The hCNT1 nucleoside transporter preferentially transports pyrimidine 
nucleosides such as thymidine, cytidine, and uridine with high affinity,30, 31 with Km 
values in the low micromolar range. Interestingly, hCNT1 does transport adenosine in a 
high affinity low capacity manner;32, 33 but, it does not transport purine nucleosides such 
as, guanosine and inosine, or their analogs. The hCNT1 protein also does not interact 
with either nucleobases or nucleotides. Transport across hCNT1 has a sodium to 
nucleoside ratio of 1:1 (Na+/nucleoside).32 The hCNT1 nucleoside transporter also 
accepts a number of pyrimidine and adenosine analogs as substrates.34 Gemcitabine, an 
anticancer drug, is a high affinity substrate of hCNT1 which exhibits an efficiency similar 
to that of hENT1.35 5′-Deoxy-5-fluorouridine, an intermediate metabolite of the 
anticancer drug capecitabine is also an hCNT1 substrate.36 
 
The transport of nucleosides across the hCNT2 transporter appears to be 
mechanistically similar to hCNT1 mediated transport. However, unlike hCNT1, hCNT2 
is involved in the transport of purine nucleosides such as adenosine, guanosine and 
inosine.21, 22 The only exception is that of the pyrimidine nucleoside, uridine, which is 
transported by this transporter.37 The ratio of Na+ to nucleoside transport via hCNT2 is 
1:1.38 A number of nucleoside analogs used in therapeutics are known to interact with the 
hCNT2 transporter. A number of fluorouridine analogs interact with hCNT2 and 5-FU is 
transported by hCNT2 with kinetics similar to that of uridine.37 However, other drugs 
such as AZT, ddI (2′,3′-dideoxyinosine), ddC (2′,3′-dideoxycytidine), ddA (2′,3′-
dideoxyadenine), Ara A (adenine arabinoside), FdU (5-fluorodeoxyuridine), and IdU 
(Idoxuridine) are not substrates of hCNT2.37 Species specific differences in interaction 
with nucleoside analogs between rat and human CNT2 transporters have been observed. 
For instance, ddI which is not a permeant for the hCNT2, is transported by rCNT2 (Km= 
29.2 μM).37 
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Mechanistically, CNT3 differs from CNT1 and CNT2 in two aspects. CNT3 
employs a 2:1 Na+ nucleoside coupling ratio in contrast to the 1:1 ratio employed by 
CNT1 and CNT2.23, 39 Physiologically, this means that CNT3 can concentrate nucleosides 
10 times more than CNT1 or CNT2. Hence, CNT3 mediated transport of nucleosides and 
nucleoside analogs are important even in tissues such as the kidney where lower levels of 
this transporter are expressed. CNT3 also exhibits a broad selectivity for nucleoside 
substrates by transporting both purine and pyrimidine nucleosides. Hence CNT3 interacts 
with a much broader range of therapeutic nucleoside analogs and is expected to play an 
important role in the absorption, distribution and elimination of nucleoside drugs. hCNT3 
is known to transport both purine and pyrimidine nucleosides with high affinity, 
exhibiting Km values ranging from 15 μM for adenosine and cytidine to 53 μM for 
inosine.23, 40 The hCNT3 transporter efficiently transports pyrimidine nucleoside analogs 
such as 5-fluorouridine, 5-fluoro-2′-deoxyuridine and gemcitabine. It is also known to 
transport purine nucleoside analogs such as cladribine and fludarabine.23 Low uptake of 
nucleoside analogs such as AZT, ddI, and ddC has also been observed. 
 
 Although the three concentrative nucleoside transporters, CNT1, CNT2 and 
CNT3 have been cloned and characterized, the proteins that demonstrate N4-cit-like, N5-
cs or N6-csg activities have not yet been identified. The N4-cit-like system is selective  
for pyrimidine nucleosides but also accepts adenosine and guanosine, N5-cs system 
transports adenosine and its analogues, and N6-csg activity is guanosine- 
selective.29, 31, 41-44  
 
 
1.2.4 Molecular Determinants of Concentrative Nucleoside Transporter   
            Substrates 
 
Uridine and adenosine are two common permeants of the three major 
concentrative nucleoside transporters CNT1, CNT2, and CNT3. A number of uridine 
analogs have been studied to evaluate the transportability profile of these three 
concentrative nucleoside transporters.45-47 
 
The C3′-OH has been identified to be a critical functional group for high affinity 
binding of uridine analogs to the CNT1 transporter.45 Any modification, such as addition 
of bulk at this position has resulted in decreased transportability of uridine analogs. The 
C5 and the N3 positions of uridine have also been identified as important regions for 
hCNT1-mediated transport. The C2′-OH is relatively unimportant for hCNT1-uridine 
interactions as uridine analogs with modification at this position were both good 
inhibitors and good permeants. The C5′-OH has also been identified for high affinity 
hCNT1-uridine interactions but was not essential for transportability. 
 
 The C3′-OH and C5′-OH groups have been identified as functional groups 
important for high-affinity interactions between hCNT2 and uridine analogs.46, 47 
Modifications to these two hydroxyls which may include substitution, removal of the 
hydroxyl groups or inversion of configuration at the C3′-OH may yield molecules that are 
either poor permeants or no permeants at all. The N3-H atom is also critical for binding. 
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The C2′-OH and C5 positions are also important structural requirements at the hCNT2 
transporter. Removal of the C2′-OH group is tolerated but its inversion is not. Also, 
addition of bulk, such as azido or methyl groups, at the C2′ position is not tolerated. 
Addition of halogens, methyl or ethyl groups to the C5 position of uridine analogs also 
leads to loss of affinity for the hCNT2 transporter. 
 
For the interaction of uridine analogs with hCNT3, the C3′-OH group is one of the 
most important functional groups. Removal or modification of this functional group leads 
to significant loss of affinity and transport of nucleoside analogs. The C2′-OH and C5-OH 
positions are relatively unimportant for transport and binding. The C5 and N3 
modifications also cause no substantial changes in hCNT3 binding, identifying them as 
minor determinants for hCNT3 transportability. 
 
 
1.2.5  Concentrative Nucleoside Transporter Inhibitors 
 
Understanding the molecular requirements at the concentrative nucleoside 
transporters can guide the rational design of nucleoside transporter inhibitors to be 
developed for application in various disease conditions. To date, only a very limited 
number of potent inhibitors have been identified for these transporters. Knowledge 
regarding concentrative nucleoside transporter inhibitors is also limited, and potent 
inhibitors are actively being pursued. The few inhibitors known in the literature are: 
 
• Phloridzin,48 
• 5′-position modified nucleoside derivatives of adenosine,49 
• Benzimidazole ribofuranosides,50 
• 8-position modified purine nucleoside derivatives51 
 
 
1.2.5.1  Phloridzin 
 
Phloridzin (I), a dihydrochalcone glucoside, is a mild to moderate inhibitor of the 
three major sodium-dependent NTs (Figure 1.6). It inhibits CNT1 with an IC50 of 250 
μM, CNT2 with an IC50 of 100 μM and CNT3 with a Ki of 15 μM at CNT3.48 An 
addition, phloridzin has also been shown to inhibit concentrative nucleoside transport in 
rat intestinal epithelium with an IC50 of  700 μM and in renal brush border membranes 
with an IC50 of 60 μM.52 
 
 
1.2.5.2  5′-Position Modified Nucleoside Derivatives of Adenosine 
 
The synthesis and CNT2 inhibitory activity of 5′-position modified nucleoside 
derivatives of adenosine was described in a 2004 Japanese patent 49 (Figure 1.6). 
Compound II, is representative of this class, and exhibited an IC50 of 3.1 μM against the  
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Figure 1.6:  CNT inhibitors 
 
 
CNT2 transporter. The compounds synthesized and tested in this patent have been 
claimed to be useful for the treatment of hyperuricemia, gout and hyperuric nephropathy. 
 
 
1.2.5.3  Ribofuranoside Compounds with Benzimidazole Moiety 
 
 Another Japanese patent describes the synthesis and CNT2 mediated adenosine 
uptake inhibition assays for a class of modified nucleoside analogs50 (Figure 1.6). These 
compounds have a ribofuranose moiety as the glycone unit but have a benzimidazole 
moiety as the aglycone unit. One of the potent compounds from this class is compound 
III. The IC50 of compound III was found to be 9 nM. These compounds have also been 
claimed to be useful for hyperuricemia, gout and hyperuric nephropathy. 
 
 
1.2.5.4  8-Position Modified Purine Nucleoside Derivatives 
 
A class of 8-position modified purine nucleoside derivatives has been described 
by Tatani et al. in a Japanese patent51 (Figure 1.6). As in the earlier case, these 
compounds have also been studied as inhibitors of CNT2. Compound IV, which is 
representative of this class of compounds, inhibited the uptake of [14C]-adenosine 
mediated by hCNT2 transporter expressed in COS-7 cells with an IC50 of 297 nM. These 
compounds have been claimed to be useful for the treatment or prevention of diseases 
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attributable to abnormality in plasma uric acid, in particular gout, hyperuricemia, urinary 
stones or acute hyperuric neuropathy. 
 
 
1.3  Equilibrative Nucleoside Transporters 
 
The equilibrative nucleoside transporters mediate low affinity, bi-directional 
facilitated diffusion transport processes and are widely distributed in the body. They 
belong to the SLC29 family of proteins.53 The general topology of human equilibrative 
nucleoside transporters (hENTs) consists of 11 transmembrane (TM) domains with a long 
extracellular loop between transmembrane domains 1 and 2 and a much longer 
cytoplasmic loop between transmembrane domains 6 and 7.54 (Figure 1.7) Of the four 
identified ENTs, ENT1 and ENT2, have been well characterized, whereas the other two, 
ENT3 and ENT4 were identified recently and isolated as a result of the completion of the 
human genome project. Human ENT1 was formerly referred to as the es (equilibrative 
inhibitor-sensitive) nucleoside transporter and ENT2 was referred to as the ei 
(equilibrative inhibitor-insensitive) nucleoside transporter earlier based on their 
sensitivity to inhibition by S6-(4-nitrobenzyl) mercaptopurine riboside (NBMPR) (V) and 
its congeners.55 Some of the other potent inhibitors of ENTs include coronary vasodilator 
drugs such as dipyridamole (VI), draflazine (VII), and dilazep (VIII) (Figure 1.8). 
 
 
1.3.1  Molecular Characteristics 
 
Human ENT1 (hENT1) is a 456-residue glycoprotein with an intracellular N-
terminus and a short extracellular C-terminus.57 hENT1 is highly sensitive to inhibition 
by NBMPR at the nanomolar concentration (Ki = 0.1-1.0 nM). It is glycosylated at 
Asn-48 in the extracellular loop between TMs 1 and 2,58 and although glycosylation is 
not required for transport of nucleosides by hENT1, it may have an effect on the binding 
affinity of transport inhibitors such as NBMPR.58 The hENT1 protein is 78 % identical in 
sequence to its 457-residue rat homolog (rENT1)59 and 79 % identical to the 460-residue 
mouse homolog (mENT1.1).60, 61 Relative to hENT1, rENT1 has been shown to be rather 
resistant to inhibition by dipyridamole, dilazep and draflazine. Dipyridamole inhibited 
hENT1 with an IC50 value of 190 nM whereas it inhibited rENT1 with an IC50 value ≥ 10 
μM when competitive inhibition experiments were conducted using 10 μM uridine.54  
 
 The amino terminal half of hENT1 has been identified as the major site of 
interaction for vasodilator drugs.54 Studies have been carried out to identify the amino 
terminal half of rENT1 as also involved in the transport inhibitory activity of NBMPR. 
Replacing the amino terminal half of  rENT1 with that of the NBMPR insensitive 
transporter rENT2 rendered rENT1 insensitive to NBMPR.62 Transmembrane domains 3-
6 have been identified as the NBMPR binding domains within the ENT1 transporter.62 
 
 The human ENT2 (hENT2) transporter was cloned from HeLa cells63 and human 
placenta.64 Human ENT2 function is weakly inhibited by NBMPR.65 hENT2 is a 456-
residue protein that is 46 % identical in amino acid sequence to hENT1. As in the case of  
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hENT1, it is also predicted to be an 11 transmembrane domain protein. The most 
homologous regions between hENT1 and hENT2 are the transmembrane segments, 
whereas the hydrophilic termini and loops are the least homologous. The hENT2 
transporter protein is glycosylated at two sites- Asn48 and Asn57.66 Glycosylation is 
required for the efficient targeting of the hENT2 protein to the plasma membrane. 
However, glycosylation is not known to change the function of hENT2. The rat and 
mouse orthologs of the ENT2 protein, rENT2 and mENT2, respectively, have also been 
cloned.59, 61 
 
 
1.3.2  Tissue Distribution 
 
The hENT1 protein is ubiquitously distributed in a variety of human tissues 
although its abundance in tissues varies. High expression levels of the hENT1 protein or 
mRNA have been observed in a number of different tissues such as erythrocytes, 
placenta, brain, heart, liver, lung and colon.67, 68 The co-localization of hENT1 and A1 
receptors suggests an important role of hENT1 in the neuromodulatory actions of 
adenosine in the human brain69. Similarly, abundant expression of the rENT1 protein in 
cardiac atrial and ventricular cells and the sinoatrial node suggests an important role for 
the ENT1 transporter in regulating the local concentrations of adenosine in the heart.68 
hENT2 mRNA is expressed in a wide range of tissues including brain, heart, placenta, 
thymus, pancreas, prostate and kidney, but is particularly abundant in skeletal  muscle.63, 
67 hENT2 transporter protein is also found in certain tumor tissues obtained from kidney, 
breast, prostate, colon and stomach.67 
 
 
1.3.3  Transport of Physiologic Nucleosides and Nucleoside Analogs 
 
The hENT1 transporter protein stably expressed in a nucleoside transporter-
deficient cell line, PK 15, exhibits a broad substrate specificity for both purine and 
pyrimidine nucleosides. The Km values for different nucleosides range from 50 μM for 
adenosine to 680 μM for cytidine.70 However, hENT1 is unable to transport nucleobases. 
The hENT1 protein also interacts with a number of nucleoside analogs used in the 
treatment of cancer and viral infections. The poor transport of a number of 3′- deoxy 
nucleosides, such as 2′,3′-dideoxycytidine (ddC), 2′,3′-dideoxyinosine (ddI) and 3′-azido-
3′-deoxythymidine (AZT) routinely used as antiviral agents, indicates that the presence of 
a 3′-hydroxyl group is important for the recognition of nucleosides as substrates by the 
hENT1 protein.71  
 
 Similar to the hENT1 nucleoside transporter, hENT2 also transports a broad range 
of purine and pyrimidine nucleosides. However the apparent affinity of nucleosides 
towards hENT2 is much lower compared to hENT1, with the only exception being that of 
inosine.63, 64, 70 The hENT2 protein exhibits 7.7 and 19.3 fold lower affinities for 
guanosine and cytidine, but a 4-fold higher affinity for inosine. hENT2 is also known to 
transport a number of purine and pyrimidine nucleobases such as adenine, guanine, 
thymine, uracil and hypoxanthine.72 The nucleobases exhibit a lower apparent affinity but 
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a higher turnover number for transport compared to the corresponding nucleosides.72 
Thus, at physiological concentrations the efficiencies of nucleoside and nucleobase 
transport by the ENT2 transporter are similar. In contrast to hENT1, hENT2 plays an 
important role in the cellular uptake of clinical antiviral agents such as ddC, ddI and 
AZT.71 
 
 As the hENT2 protein transports dideoxynucleosides and nucleobases that do not 
bear a ribose moiety, it appears that ENT2 accepts more substrates than ENT1. A number 
of uridine and cytidine analogs have also been demonstrated to interact with hENT2 
when studied as inhibitors of [3H]-uridine uptake in yeast producing the recombinant 
protein.73 Cytidine exhibits an EC50 of 1.98 mM. Analogs of cytidine that were studied 
include 2′-deoxycytidine (EC50 = 3.06 mM), 3′-deoxycytidine (EC50 = 2.49 mM), 2′, 3′-
dideoxycytidine (EC50 = 1.10 mM) and araC (EC50 = 1.20 mM). Similarly, a number of 
uridine analogs such as 5-fluorouridine, 5-iodouridine, 2′-deoxyuridine, 5-fluoro-2′-
deoxyuridine, and 5-bromo-2′-deoxyuridine displayed EC50 values in the 0.21 – 0.47 mM 
range.73  
 
Human ENT3 is a 475-residue protein displaying 73 % identity to the mouse 
homologue (mENT3).1, 74-76 ENT3 has a characteristic, long (51 aa) hydrophilic N-
terminal region preceding the first transmembrane (TM1) domain. The N-terminal region 
of ENT3 consists of two dileucine motifs characteristic of endosomal and lysosomal 
targeting motifs. This architectural design distinguishes the ENT3 protein from other 
members of the equilibrative transporter family. 
 
Indeed, it was demonstrated that hENT3 protein is predominantly localized 
intracellularly and that mutation of the dileucine motif to alanine triggers the relocation 
of ENT3 protein to the cell surface.74, 75  In comparison to ENT1, the ENT3 transporter is 
much less susceptible to inhibition by NBMPR and coronary vasodilatory drugs like 
dipyridamole and dilazep. Human ENT3 demonstrates a broad selectivity for nucleosides, 
but does not transport hypoxanthine. hENT3 facilitates the transport of several adenosine 
analogues like CdA and cordycepin (3’-deoxyadenosine). The antiviral purine and 
pyrimidine nucleoside analogues ddI, ddC and in particular AZT are efficiently 
transported by this protein.74, 75 
 
 Human ENT4 is a 530-residue protein displaying 86 % identity to its 528-residue 
mouse homologue.74 The substrate specificity of hENT4 has not been determined in 
detail, but among ENT proteins, hENT4 has the lowest affinity for adenosine.77 ENT4, is 
abundant in the heart, in particular in the plasma membranes of ventricular myocytes and 
vascular endothelial cells and is virtually absent from the sinoatrial and 
atrioventricular nodes. Originally described as a monoamine/organic cation transporter, it 
was found that both human and mouse ENT4 exhibited a novel, pH-dependent adenosine 
transport activity optimal at acidic pH (apparent Km values 0.78 and 0.13 mmol/L, 
respectively, at pH 5.5) and absent at pH 7.4. In contrast, serotonin transport by ENT4 
was relatively insensitive to pH. ENT4-mediated nucleoside transport was adenosine 
selective, sodium independent and only weakly inhibited by the classical inhibitors of 
equilibrative nucleoside transport, dipyridamole, dilazep, and nitrobenzylthioinosine. 
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It is predicted that in addition to playing roles in cardiac serotonin transport, ENT4 
contributes to the regulation of extracellular adenosine concentrations, in particular under 
the acidotic conditions associated with ischemia.78 
 
 
1.3.4  Equilibrative Nucleoside Transporter Inhibitors 
 
There are different classes of compounds significantly active as inhibitors against 
ENTs. Some of these classes are as follow: NBMPR (V) and derivatives79-85, C8-
alkylamine substituted purines85, pyrimidopyrimidines and pteridines86, 87 (e.g. 
dipyridamole, VI); alkyl, cycloalkyldiamine and piperazine compounds88, 89 (e.g. 
draflazine, VII and dilazep, VIII), Protein kinase inhibitors24, 90, cannabinoids91 (e.g. 
THC); adenosine receptor ligands92 (e.g. propentofylline); dihydropyridine calcium 
channel blockers93-95 (e.g. nimodipine), verapamils92, benzodiazepines96, 97 (e.g. 
diazepam), epipodophyllotoxins98-100 (e.g. etoposide), thiazolidinediones101 (e.g. 
troglitazone), xanthine oxidase inhibitors102, organomercurials103, 104 (e.g. p-
chloromercuriphenyl sulphonate) and some belonging to miscellaneous category. Figure 
1.8 lists some of the above mentioned compounds. 
 
 
1.4  Applications of Nucleoside Transporter Inhibitors 
 
Nucleoside transporters have potential to serve as pharmacological targets in a 
variety of important disease areas. Nucleoside transport inhibitors can be used in 
1) antimetabolite potentiation, 2) adenosine potentiation, and 3) host tissue protection. 
Each of the three areas of application has been outlined in the following sections. 
 
 
1.4.1  Antimetabolite Potentiation 
 
 
1.4.1.1  Cancer Chemotherapy 
 
In the early 1980s it was observed that the cytotoxic effect of de novo pathway 
inhibitors such as 5-fluorouracil and methotrexate on tumor cells were overcome by 
nucleotide biosynthesis via the salvage pathways.105 Hence it was thought that combining 
de novo pathway inhibitors with salvage pathway inhibitors can increase effective cell 
kill. Weber and coworkers first explored this biochemical modulation of antimetabolite 
chemotherapy by combining them with nucleoside transport inhibitors.106, 107 Since then, 
the therapeutic promise of combining nucleoside transport inhibitors with antimetabolite 
anticancer agents such as 5-fluorouracil and methotrexate has been demonstrated in 
several experimental studies. The anticancer activity of lipophilic analogs of cytotoxic 
nucleosides such as N4-hexadecyl-1-β-D-arabinofuranosylcytosine (NHAC) which enter 
cancer cells by passive diffusion can also be potentiated by nucleoside transport 
inhibitors. Nucleoside transport inhibitors in this case will suppress competition from 
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extracellular physiological nucleosides and thus enhance the antitumor activity of 
NHAC.108 
 
 
1.4.1.2  Viral Infections 
 
Nucleobase or nucleoside antimetabolites are commonly used in the treatment of 
viral infections. In the treatment of HIV infections, AZT and related dideoxynucleoside 
reverse transcriptase inhibitors were the first agents with clinical utility. Majority of 
dideoxynucleosides including AZT enter the cell mainly by passive diffusion whereas 
nucleoside transporters are responsible for the entry of endogenous nucleoside 
competitiors such as thymidine. Hence nucleoside transport inhibitors can shut out the 
competition from endogenous nucleosides. Studies in this direction have successfully 
demonstrated the advantages of such a combination therapy.109 
 
 
1.4.2  Adenosine Potentiation 
 
 
1.4.2.1  Cardioprotection 
 
Endogenous adenosine protects the heart against ischemic and reperfusion tissue 
injury by 1) vasodilatation via adenosine A2- receptors, causing increased coronary blood 
flow to increase local oxygen supply, 2) inhibition of catecholamine release and action, 
thereby preventing cardiac overstimulation, 3) inhibition of neutrophil adherence and 
release of tissue damaging reactive oxygen metabolites through A2a receptor activation 
action,110 and 4) preconditioning through A1 and A3 receptors.111, 112 During cardiac 
ischemia and reperfusion, the action of adenosine produced locally to protect against 
tissue injury is short-lived mainly due to uptake into endothelial cells and inactivation by 
adenosine deaminase. Interaction of adenosine with the A2 receptor is also known to 
stimulate its own transport.113 Hence, nucleoside transport inhibitors can be employed to 
prevent adenosine uptake by the endothelial cells leading to prolonged local effect of 
adenosine. The use of nucleoside transport inhibitors in cardioprotection is attractive 
because the release of adenosine in ischemia is transient and localized in the tissue under 
ischemic stress. As a result activation of adenosine receptors all over the body of the 
patient would not occur in this case leading to decreased side effects as compared to 
adenosine receptor agonists. 
 
 
1.4.2.2  Ischemic Preconditioning and Heart Transplantation 
 
In preconditioning, the patient is made more resistant to future ischemic injury 
and adenosine transport inhibitors have been shown to have potential utility in this 
condition.114, 115 During heart transplantation nucleoside transporter inhibitors can 
potentially improve the long term ex vivo storage of hearts.116 Nucleoside transport 
inhibitors have also been found to be useful in intra-operative myocardial protection.117 
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1.4.2.3  Neuroprotection and Stroke 
 
The neuroprotective action of extracellular adenosine released during cerebral 
ischemia is terminated primarily due to its uptake into the surrounding cells via 
nucleoside transporters. These protective effects of extracellular adenosine can be 
prolonged by the use of nucleoside transport inhibitors.118 The presence of multiple 
subtypes of nucleoside transporters in the central nervous system offers the potential for 
the development of drugs with selectivity for certain areas of the brain. Propentofylline, a 
xanthine derivative with moderate nucleoside transporter inhibitory activity and good 
CNS penetration has been shown to prevent ischemia-induced brain damage in 
Mongolian gerbils and in rats.119 In rat hippocampal slices, propentofylline, NBMPR and 
other nucleoside transport inhibitors have been shown to increase extracellular adenosine 
levels. The reduction in neurotransmitter release following adenosine potentiation by 
nucleoside transport inhibitors has been suggested as a therapeutic strategy in stroke.120 
 
 
1.4.2.4  Anti-inflammatory Effects 
 
During inflammation, adenosine is released and it acts as an endogenous anti-
inflammatory agent.121 Adenosine A2a receptors have an important role in the anti-
inflammatory effects of adenosine.122 Adenosine broadly inhibits neutrophil functions123 
(e.g., oxygen radical production, adhesion to vascular endothelium, injury to endothelial 
cells, phagocytosis and arachidonic acid release), macrophage functions124 (e.g., 
production of pro-inflammatory cytokines), and endothelial cell activation125 (e.g., 
cytokine release and adhesion molecule expression) leading to its anti-inflammatory 
effects. However, these effects of adenosine are insufficient because of the rapid uptake 
and metabolism of adenosine by adjacent cells. Thus nucleoside transport inhibitors can 
be used to prevent this adenosine reuptake into the surrounding cells and thus bring about 
adenosine potentiation. The nucleoside transport inhibitor, dipyridamole has been 
reported to inhibit inflammatory events both in vitro and in vivo126 in models of 
inflammatory diseases such as glomerulonephritis.127 
 
 
1.4.3  Host Tissue Protection 
 
 
1.4.3.1  Protection against Nucleoside Anticancer Drugs Toxicity 
 
One of the major drawbacks of current cancer chemotherapy is the immense 
suffering caused in patients as a result of host tissue toxicity. This not only prevents dose 
escalation but in many patients also leads to discontinuation of chemotherapy. The 
combination of nucleoside anticancer agents with nucleoside transport inhibitors has been 
shown to protect against host tissue toxicity.128-130  
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1.4.3.2  Antiprotozoal Chemotherapy 
 
Nucleoside transporter inhibitors have been used for host tissue protection during 
experimental treatment of schistosomiasis,131-133 trypanosomiasis,134 and leishmaniasis135. 
However, certain parasites are known to induce the expression of new inhibitor resistant 
transporters in the infected mammalian host cells which has been best demonstrated in 
mammalian erythrocytes infected with malarial parasites.136 This altered purine 
nucleoside transport in plasmodium infected erythrocytes has been proposed as a target 
for developing novel antimalarial therapies. Selectivity can be achieved by combining 
antimalarial nucleosides with nucleoside transport inhibitors which will protect normal 
cells but not plasmodium infected cells against the cytotoxic nucleoside analogs.137 
Toxoplasma gondii is another opportunistic obligate intracellular parasite responsible for 
causing toxoplasmic endocephalitis in AIDS patients. This parasite is dependent entirely 
on purine and purine nucleoside salvage for its metabolic and growth requirements.138, 139 
The parasite expresses a single dipyridamole sensitive nucleoside transporter which is not 
inhibited by NBMPR even at concentrations as high as 15μM.140 Hence there is a 
possibility of combining adenosine analogs with NBMPR for treatment of Toxoplasma 
infections in AIDS patients. 
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Chapter 2: Research Objectives 
 
 
The cellular uptake and efflux of nucleosides are mediated by specialized 
transmembrane proteins known as NTs. As mentioned in Chapter 1, NTs can be 
classified into two families, namely, bidirectional sodium-independent equilibrative 
nucleoside transporters (ENTs) and unidirectional sodium-dependent concentrative 
nucleoside transporters (CNTs). Different isoforms of each of these classes have been 
identified, and some have been cloned and extensively characterized. The substances that 
inhibit nucleoside transporters have potential therapeutic applications in the treatment of 
various diseases such as cancer, HIV infection, cardiac ischemia, stroke and 
inflammation. However, the available NT inhibitors are largely unsuitable for clinical 
development and thus the need for novel inhibitors. ENT 2, 3 and 4 and most CNT family 
members lack potent inhibitors, which limits their biological characterization and 
therapeutic targeting. This research was thus conducted to identify novel selective NT 
inhibitors as biological probes and potential therapeutic lead compounds.  
 
In the absence of a three dimensional structure of any nucleoside transporter or its 
co-crystal with inhibitors, drug discovery for this class of targets depends on ligand-based 
approaches. The main reason for studying flavones and related compounds is their 
structural resemblance to phloridzin, a naturally occuring dihydrochalcone glucoside that 
has demonstrated low to moderate inhibitory activity against the three major 
concentrative nucleoside transporters, CNT1, CNT2 and CNT3 (Figure 2.1). Flavones 
were also suggested as potential nucleoside transporter inhibitors in a nucleoside 
transporter inhibition pharmacophore analysis study carried out by our laboratory and 
collaborators.141  In that study, fifteen known inhibitors of equilibrative nucleoside 
transpoters comprising derivatives of NBMPR, pyrimidopyrimidines, pteridines and 
flazines were used to derive a common feature hypothesis. The generated pharmacophore 
was used for database searching, which returned hits that included flavone and isoflavone 
structures suggesting that flavones can be analyzed for nucleoside transporter inhibition.  
Thus, it was of interest to investigate the inhibitory activity of flavonoids against both the 
CNT and ENT classes of NTs. Hence, flavones and analogs including coumarins, 4H-
benzopyrans and a quinoxaline derivative were tested against hCNT1, hCNT2, hCNT3, 
hENT1 and hENT2 transport function. The results obtained were used to gain insights 
into the structure-activity relationships of flavonoids regarding these five nucleoside 
transporters. 
 
 
       Phloridzin                     Flavone glucoside  
 
Figure 2.1:  Structural resemblance of phloridzin to flavone 
O
OHH
OH
H
OH
H
O
H
OH H
O
OH OH OH
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The specific aims of this research were: 1) to conduct biological evaluation of a 
series of flavones and related compounds as concentrative and equilibrative nucleoside 
transporter inhibitors, 2) to use the biological data for structure-activity relationship 
information and to build 3D-QSAR models which can be further used for in silico drug 
design of flavonoid-based nucleoside transporter inhibitors. The cumulative data obtained 
in this manner using flavonoids and related compounds, can be further used for hit 
identification and lead optimization to obtain new potent and selective nucleoside 
transporter inhibitors. 
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Chapter 3: Biological Evaluation and 3D-QSAR Studies of Flavone Analogs for    
Human Concentrative Nucleoside Transporter Inhibition 
 
 
3.1  Introduction 
 
In this chapter, the findings on a series of flavone analogues as CNT inhibitors are 
presented. The compounds were tested against the three cloned human CNT transporters, 
hCNT1, hCNT2 and hCNT3. The biological activity data were used to derive CoMFA 
and CoMSIA 3D-QSAR models, which were further used for insights on the influence of 
physicochemical descriptors and in silico activity prediction. 
 
 
3.2  Uridine Uptake Assay 
 
A uridine uptake assay was used to measure the function of transporters, entails 
the measurement of the uptake of radiolabeled uridine and inhibition by test compounds. 
The cell line that was used for the study is the nucleoside transporter deficient PK15NTD 
cell line stably transfected with hCNT1, hCNT2 or hCNT3 cDNA. The amount of 
radiolabeled uridine present intracellularly following a two-minute exposure to CNTs, is 
determined in the absence and presence of varying concentrations of test compounds. 
After the uptake, the radiolabeled uridine present extracellularly is washed off and then 
the cells are lysed with an appropriate detergent and the radioactivity is measured. The 
amount taken up by the cells is highest in the absence of an inhibitor and decreases in the 
presence of an inhibitor. Thus, by appropriately varying the inhibitor concentrations 
suitable dose-response curves can be developed and IC50 (concentration that causes 50 % 
inhibition) values can be determined. Using the above assay procedure, compounds used 
in the study were first screened at a concentration of 10 μM. Only those compounds 
showing more than 50 % inhibition at 10 μM were further analyzed for IC50 
determination. The IC50 values thus obtained were further converted to the corresponding 
Ki values using the Cheng-Prusoff equation.142 The Ki values were used to compare the 
abilities of compounds to inhibit individual CNT transporters, and their affinity as well. 
Details of the [3H]-uridine uptake assay are provided in the experimental section of this 
chapter. Phloridzin was used as a standard to compare the inhibitory activities of the rest 
of the compounds. 
 
 
3.3  IC50 Curves of Active Flavones 
   
     The screening (Figure 3.1) and IC50 value determination of compounds as hCNT1 
and hCNT2 inhibitors was carried out by Dr. Chunmei Wang, who is a postdoctoral 
fellow in our laboratory. The structures of all ninety five compounds and their IC50 values 
against hCNT1, hCNT2 and hCNT3 are presented in Table 3.1. Figure 3.2 shows the IC50 
curves for compounds active against hCNT3. 
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Figure 3.1:  Comparison graph of % of inhibition at 10 μM concentration by compounds against hCNT1, hCNT2 and hCNT3 
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Table 3.1: Compounds evaluated for CNT inhibition with IC50 values 
 
O
O
R2
Flavone (A) Chalcone (B)
R3
R5
R6
R7
R8
O R2
R3
R5
R6
R7
R8
N
N R2
R3
R5
R6
R7
R8
R4
O O
R3
R5
R6
R7
R8
R4O
R2
R5
R6
R7
R8
Coumarin (C) (D) Quinoxaline (E)  
 
Compound Type R2 R3 R4 R5 R6 R7 R8 hCNT1 
IC50 (µM) 
hCNT2 
IC50 (µM) 
hCNT3 
IC50 (µM) 
            
Phloridzin - - - - - - - - 247.30 ±  2.10 121.00  ±  1.70 25.13 ±  3.75 
1 A 4-bromophenyl H C=O H Cl CH3 H - - - 
2 A 4-hydroxyphenyl OH C=O H H H H - - 55.68 ±  4.50 
3 A 3,4-dihydroxyphenyl H C=O H H OH H - 28.84 ±  1.40 11.29 ±  3.79 
4 A Phenyl OH C=O OH H H H - - 34.36 ±  1.00 
5 A Phenyl OH C=O H OH H H - - 11.00 ±   3.57 
6 A Phenyl OH C=O H H OH H - - 104.07 ±  26.81 
8 A 4-hydroxyphenyl H C=O H OH H H - - 22.26 ±  5.98 
9 A Phenyl H C=O H OH OH H 30.67 ±  1.40 40.43 ±  1.50 71.74 ±  5.83 
10 A 2-hydroxyphenyl H C=O H H OH H - - 18.07 ±  4.02 
11 A 3-hydroxyphenyl H C=O H H OH H 41.69 ±  1.50 13.80 ±  1.40 8.86 ±  3.78 
12 A 4-hydroxyphenyl H C=O H H OH H 35.75 ±  1.50 24.40 ±  1.30 4.74  ±  1.13  
13 A Phenyl H C=O H H OH OH 40.43 ±  1.50 3.38 ±  1.10 1.62 ±  0.81 
14 A 4-hydroxyphenyl H C=O OH H OCH3 H - -   74.00 ±  6.85 
15 A Phenyl H C=O OH OH OCH3 H - 100.00 ±  1.70 26.26 ±  3.60 
16 A 3,4,5-trimethoxyphenyl OH C=O H H OH H - 43.10 ±  1.20 34.34 ±  2.79 
17 A 3-hydroxy-4-
methoxyphenyl 
H C=O OH OCH3 OCH3 H - - 17.15 ±  1.61 
18 A 2,3-dimethoxyphenyl H C=O H H H H - - -  
19 A 4-methoxyphenyl OCH3 C=O H H H H - - 64.60 ±  2.61 
 
20 A 3,4-dimethoxyphenyl H C=O H H H H - - - 
22 A Phenyl H C=O H OCH3 OCH3 H - - 176.73 ±  20.97 
23 A 3,4-dimethoxyphenyl OH C=O H H H H - - 18.07  ±  4.02 
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Table 3.1: (continued) 
 
Compound Type  R2  R3 R4 R5 R6 R7 R8 hCNT1 
IC50 (µM) 
hCNT2 
IC50 (µM) 
hCNT3 
IC50 (µM) 
            
24 A 2,3-dimethoxyphenyl OH C=O H H H H - - - 
25 A 2,4-dimethoxyphenyl  C=O H H H H - - - 
26 A 2-methoxyphenyl OH C=O H OCH3 H H - - - 
27 A 3-methoxyphenyl OH C=O H OCH3 H H - - 22.92 ±  7.02 
28 A 4-methoxyphenyl OH C=O H OCH3 H H - - - 
30 A 3-methoxyphenyl OH C=O H H OCH3 H - - 56.25 ±  8.47 
31 A 2,4-dimethoxyphenyl OH C=O H CH3 H H - - 28.15 ±  5.75 
32 A 3,4-dimethoxyphenyl OH C=O H CH3 H H - - 32.08 ±  4.49 
33 A 3,4-dimethoxyphenyl H C=O OH OCH3 OCH3 H - - 16.16 ±  3.06 
34 A 3,4-dihydroxyphenyl OH C=O H H OH H 26.30 ±  1.20 8.80 ±  1.20 4.25 ±  0.53 
35 A 3,4,5-trimethoxyphenyl H C=O OH OCH3 OCH3 OCH3 - - 49.83 ±  7.98 
36 A 3,4,-dihydroxyphenyl OH C=O OH H OH OH - - - 
37 A 3,4,-dihydroxyphenyl OH C=O OH H OH OGlu - - - 
38 A 3,4,5-trimethoxyphenyl H C=O OCH3 OCH3 OCH3 H - - - 
39 A Phenyl H C=O H OH OCH3 H - - 0.57 ±  0.20 
40 A 4-methoxyphenyl H C=O H H OH H - - 27.18 ±  7.25 
41 A 3,4,5-trimethoxyphenyl OH C=O H H OCH3 H - - -  
42 A 3,4,5-trimethoxyphenyl OH C=O H H H H - - 18.04 ±  2.71  
43 B 2-hydroxy-4-
methoxyphenyl 
- C=O H OCH3 H H - - 23.34 ±  5.57 
44 B 3,4-Dimethoxy-2-
hydroxyphenyl 
- C=O H H H H - - 24.27 ±  3.08 
45 B 2-hydroxy-4-
methoxyphenyl 
- C=O H H OCH3 H - - 44.14 ±  8.10 
46 B 2-hydroxy-5-
methylphenyl 
- C=O OCH3 H OCH3 H - - 43.44 ±  9.60 
47 B 2-hydroxy-5-
methylphenyl 
- C=O OCH3 H H OCH3 - - 51.44 ±  4.26 
48 A 2-phenyl H C=O OH OH OH H 23.99 ±  2.30 67.22 ±  1.60 29.83 ±  11.98 
49 A 3-hydroxyphenyl H C=O H H OH OH 11.75 ±  1.70 1.66 ±  1.10 7.18 ±  1.76 
50 A 4-hydroxyphenyl H C=O H H OH OH 29.39 ±  1.70 5.25 ±  1.10 0.68 ±  0.23 
51 A 3,4-dihydroxyphenyl H C=O H H OH OH 25.51 ±  1.70 5.62 ±  1.10 8.45 ±   0.22 
52 A Phenyl H C=O OH OH H H - - 15.77 ±  3.60 
53 A 3-hydroxyphenyl H C=O H H OH H - 122.10 ±  9.80 - 
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Table 3.1: (continued) 
 
Compound Type R2 R3 R4 R5 R6 R7 R8 hCNT1 
IC50 (µM) 
hCNT2 
IC50 (µM) 
hCNT3   
IC50 (µM) 
            
54 A 3,4-dihydroxyphenyl H C=O H H 
 
231.74 ±  1.90 11.20 ±  1.50 32.50 ±  9.66 
55 A Phenyl H C=O H H OCH3 OCH3 - - 25.90 ±  3.96   
56 A Phenyl H C=O H H OCH3 OH - - 35.55  ±  2.90 
57 A 2-hydroxyphenyl H C=O H H OH OH 16.60 ±  1.50 4.06 ±  1.30 9.51 ±  1.67 
58 A H 4-chloro 
phenyl 
C=O H H OH CH3 - - 43.63 ±  10.1 
59 A H phenyl  C=O H H OH CH3 - - 31.62 ±  7.68 
60 A Phenyl H C=O 
 
H H - - 20.33 ±  3.53 
61 A Phenyl H  C=O H H 
 
- - 32.36 ±  0.42 
62 A 3,4-dihydroxyphenyl H C=O 
 
H H - - 13.48 ±  2.47 
63  A 3,4-dimethoxyphenyl H C=O H H 
 
- - 14.69 ±  8.00 
64 A 2-hydroxyphenyl H C=O H H 
 
- - 30.47 ±  5.10 
65 A 2-hydroxyphenyl H C=O 
 
H H - - 32.95 ±  5.99 
66 A 3-hydroxyphenyl H C=O H H  - - 16.39 ±  7.56 
67 A 3-hydroxyphenyl H C=O 
 
H H - - 16.96 ±  7.07 
 
68 A 4-hydroxyphenyl H C=O H H 
 
- - 39.51 ±  1.06 
69 A 4-hydroxyphenyl H C=O 
 
H H - - 42.00 ±   3.31 
70 A 2-phenyl OCH3 C=O H H O  
- - 20.21 ±  6.90 
71 A 4-methoxyphenyl H C=O H H 
 
- - 15.87 ±  4.85 
72 A 3,4,5-trihydroxyphenyl H C=O OH H OH H 24.73 ±  1.20 15.80 ±  1.40 6.59  ±  1.17 
73 A 4-hydroxyphenyl H C=O H H OH OGlu - - 26.97 ±  4.74 
74 A H (1-phenyl-1H- 
pyrazol-4-yl) 
C=O H H OH OH 27.90 ±  1.80 79.43 ±  3.10 7.42  ±  1.66 
75 A Phenyl H C=O H H H H - - 26.06 ±  5.48 
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Table 3.1: (continued) 
 
Compound Type R2 R3 R4 R5 R6 R7 R8 hCNT1 
IC50 (µM) 
hCNT2 
IC50 (µM) 
hCNT3 
IC50 (µM) 
            
77 A Phenyl H C=O H Cl Cl H - - 34.68  ±  8.56 
78 A H 4-chloro 
Phenoxy 
C=O H H OH OH - - 31.71 ±  5.70 
79 A H 4-Fluoro 
phenoxy 
C=O H H OH OH - - 27.06 ±   1.28 
80 A Methyl phenyl C=O H H OH OH - - 22.93 ±  1.46 
81 A H phenyl C=O H OH OH H 34.62 ±  2.10 141.00 ± 2.40 26.25 ±  4.47 
82 A H phenyl C=O H H OH OH 98.23 ±  2.70 126 ± 1.90 55.83 ±  11.99 
83 A H (4-CH3-2-
thiazoyl) 
C=O H H OH OH 51.88 ±  1.90 20.00 ± 1.60 3.02 ±  1.95 
84 A 3,4,5-trihydroxyphenyl OH C=O H H OH H 27.12 ±  2.10 13.30 ± 1.30 1.04 ±  0.60 
85 A 3,4,5-trihydroxyphenyl H C=O H H OH H 23.99 ±  1.60 8.17 ± 1.20 12.05 ±  1.17 
86a - - -  - - - - - - - 
87b - - -  - - - - - - - 
88 C C=O H CH3 H H OH NO2 - - - 
89 C C=O 4’-methoxy 
phenyl 
CH2 H H OH H 4.44 ±  1.30  - - 
90 C C=O Phenyl CH2 H OCH3 H H - - - 
91 C C=O Phenyl CH2 H H OCH3 H - - - 
92 C C=O H CH2 H  OH OH - - - 
93 C C=O H CH-
phenyl 
H OH OCH3 H - - - 
94 D 2-methyl  H H H H NH2 H - - - 
95 C C=O Phenyl OH OH H OH H - - - 
96 D 2-NH2 CN Pyridin 
-4-yl 
H H OH H - - 54.65 ±  2.03 
97 D H Phenoxy H H H OH OH - - - 
99 D 2-methyl 4’-nitro 
phenoxy 
H H H OCH3 CH3 - - - 
100 E 2-Phenyl H N H OCH3 OCH3 H - - - 
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Table 3.1: (continued) 
C
O
OH
OH
OH
HO
OH
HO
                                                                            
Br Br
O
S O
O
O
OH OH
HO OH
 
aCompound 86 (2,3,4,3’,4’,5’-hexahydroxybenzophenone)                                       bCompound 87 (Bromopyrogallol red) 
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Figure 3.2:   IC50 curves of active compounds for CNT3 inhibition 
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3.4  Materials and Methods 
 
All compounds listed in Table 3.1 were initially screened for CNT1, CNT2 and 
CNT3 nucleoside transporter inhibitory activities. Compounds showing more than 50 % 
inhibition in preliminary screening were evaluated to determine the IC50 values. The 
biological activity data was used to carry out 3D-QSAR analyses. The structures of the 
compounds and activity values (IC50 values) are shown in Table 3.1. The IC50 values 
were transformed into Ki values and the pKi values were used as the dependent variable in 
CoMFA143 and CoMSIA144 analysis. 
 
 
3.5  Molecular Modeling 
 
Three-dimensional structure building and all modeling operations were performed 
using SYBYL 7.3 (Tripos Associates Inc.) 145 on a Silicon Graphics Octane workstation. 
MOPAC charges were assigned to all molecules. Energy minimization was performed 
using the Tripos force field with a distance-dependent dielectric and the BFGS algorithm, 
with a convergence criterion of 0.01 kcal/(mole* Å). Compounds in the data set were 
aligned using the MATCH module in SYBYL. Match alignment for CoMFA and 
CoMSIA studies was performed with the core of the flavone molecule as shown in Figure 
3.3 as the template. Figure 3.4 shows the overlay of all the compounds used in the study 
aligned to the template. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                
 
 
 
Figure 3.3:  Atoms used in MATCH alignment shown in bold face 
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Figure 3.4:  Atom-by-atom compound superposition used for 3D-QSAR analysis 
 
For the molecules, red indicates oxygen, yellow refers to sulfur, grey indicates carbon, 
green indicates fluorine or chlorine and cyan indicates hydrogen. 
 
 
3.6  CoMFA and CoMSIA Models 
 
 CoMFA and CoMSIA 3D-QSAR studies were undertaken to determine the effects 
of steric, electrostatic, hydrophobic, and hydrogen bonding properties of the compounds 
on different hCNT nucleoside transporter inhibitory activities, and to obtain reliable 
models for predicting the activity of compounds that belong to the same structural class. 
CoMFA and CoMSIA descriptor fields were derived by placing the molecules in a three 
dimensional cubic lattice with a spacing of 2 Å and extending 4 Å units beyond the 
aligned molecules in all directions. CoMFA descriptors were calculated using an sp3 
carbon probe atom with a van der Waals radius of 1.52 Å and a charge of +1 with a 
distance dependent dielectric to generate steric (Lennard-Jones 6-12 potential) fields and 
electrostatic (Coulombic potential) fields at each lattice point. An energy cutoff of 30 
kcal/mole was applied. The CoMFA steric and electrostatic fields were scaled by the 
CoMFA-STD method in SYBYL. CoMSIA similarity index descriptors were calculated 
using a similar lattice box as in CoMFA. CoMSIA descriptors, namely, steric, 
electrostatic, hydrophobic, hydrogen bond donor and hydrogen bond acceptor were 
derived according to Klebe et. al144, 147 using a sp3 carbon probe atom with +1 charge and 
a van der Waals radius of 1.4 Å.146 
 
The PLS statistics obtained from CoMSIA analysis are shown in Table 3.2 and 
results obtained from PLS regression analysis, using CoMFA steric and electrostatic 
descriptors as independent variables are presented in Table 3.3. The stability of the 
CoMFA and CoMSIA models was evaluated by performing group cross-validation (30 
runs), randomization (20 runs) and bootstrapping (20 runs). The results of these 
validations are shown in Table 3.4.  
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Table 3.2: PLS statistics of CoMFA and CoMSIA 3D-QSAR models for CNT 
 
  hCNT1 hCNT2 hCNT3 
PLS statistics CoMFA CoMSIA CoMFA CoMSIA CoMFA CoMSIA 
Q2 (LOO) 0.525 0.547 0.583 0.613 0.517 0.493 
R2 0.984 0.997 0.840 0.863 0.910 0.919 
S 0.037 0.020 0.247 0.224 0.141 0.107 
F 99.22 294.01 29.67 37.69 50.26 66.26 
PLS components 5 6 3 3 7 6 
Total no. of 
compounds used for 
analysis 
 
18 
 
22 
 
64 
No. of outliers 4 5 1 None 12 12 
 
Outlier Compounds 
13,54, 
74,81 
9,54,74, 
81,84 
16 None 16,17,39,50, 
58,6,63,71,77,
80,82,9 
16,19,39,4,50,6,
63,71,73,80,82,
9 
No. of compounds in 
training set 
N/A N/A N/A N/A 43 42 
No. of compounds in 
test set 
N/A N/A N/A N/A 9 10 
Test set compounds N/A N/A N/A N/A 2,3,10,32,49, 
54, 64,70,81 
12,22,33,48,56,
61,68,75,8,84 
 
q2 = cross validated correlation coefficient; s = standard error; r2 = non-validated correlation coefficient; F = F-test value. 
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Table 3.3: Field contribution by CoMFA and CoMSIA descriptors for CNT 
 
Descriptor hCNT1 hCNT2 hCNT3 
 CoMFA CoMSIA CoMFA CoMSIA CoMFA CoMSIA 
 
Steric 
 
0.564 
 
0.074 
 
0.503 
 
0.071 
 
0.417 
 
0.064 
Electrostatic 0.436 0.710 0.497 0.327 0.583 0.432 
Hydrophobic ----- 0.210 ----- 0.149 ----- 0.162 
Donor ----- ----- ----- 0.312 ----- 0.232 
Acceptor ----- ----- ----- 0.140 ----- 0.110 
 
 
Table 3.4: Results of group cross validation, randomization and bootstrapping for 
CNT 
 
Method  hCNT1 hCNT2 hCNT3 
 CoMFA CoMSIA CoMFA CoMSIA CoMFA CoMSIA
       
Group validation q2  
(30 groups and 30 
runs)  
0.525 
± 0.030 
0.547 
± 0.029 
0.583 
± 0.015 
0.623 
± 0.009 
0.513 
± 0.023 
0.495 
± 0.012 
 
Randomization  q2 
(20 runs) 
 
- 0.371 - 0.075 - 0.150 - 0.107 - 0.005 - 0.034 
Bootstrapping (20 
runs) 
1.  r2 
0.984 
± 0.007 
0.999 
± 0.001 
0.917 
± 0.009 
0.920 
± 0.016 
0.945 
± 0.028 
0.961 
± 0.013 
2. SD 0.018 
± 0.002 
0.011 
± 0.014 
0.040 
± 0.012 
0.028 
± 0.005 
0.112 
± 0.077 
0.073 
± 0.043 
 
q2 = cross validated correlation coefficient; r2 = non-validated correlation coefficient, SD 
= standard deviation. 
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3.7  Results of 3D-QSAR Analyses 
 
  The results of the 3D-QSAR analyses are presented in the form of PLS statistics, 
fitted and prediction curves and contour isopleths. On the basis of the values of different 
statistical quantities, the QSAR results’ validity and predictive capacity was judged.  
 
The QSAR models were generated on different molecules listed in Table 3.1 for 
each nucleoside transporter. The CoMFA and CoMSIA models generated on the  
molecules show a correlation coefficient (r2) of  0.984 and 0.997 (CNT1), 0.840 and 
0.863 (CNT2) and 0.910 and 0.919 (CNT3) with cross-validated r2 (q2) of  0.525 and 
0.547 (CNT1), 0.583 and 0.613 (CNT2) and 0.517 and 0.493 (CNT3), respectively. The 
3D-QSAR models for CNT1 and CNT2 could not be validated by dividing data set into 
training and test set due to small number of compounds in both cases.  Also, only three 
descriptors were considered for CoMSIA analysis of hCNT1 to obtain good PLS 
statistics. Hence, the CNT1 and CNT2 models need refinement by testing more flavones. 
The 3D-QSAR models for CNT3 were externally validated against a test set of 9 and 10 
molecules and predictive R2 (R2 pred) recorded as 0.596 (CoMFA) and 0.569 (CoMSIA), 
respectively indicate fairly well significance of models for prediction. 
 
All the CoMFA and CoMSIA models have fairly reasonable cross validated q2 
and non-validated r2 values as presented in Table 3.2. All of the models describing 
hCNT1, 2 and 3 inhibition are statistically acceptable (q2 > ~ 0.5). The non-validated r2 
values of the CoMSIA models are similar to those of the CoMFA models for all the three 
transporters. However, if the q2 values are compared, the CoMFA model appears to be 
better than the CoMSIA model for hCNT1 and hCNT3, whereas the CoMSIA model 
appears better than the CoMFA model for hCNT2. 
 
 The outliers were decided on the basis of q2  by leave-one-out cross-validation. In 
generating the model for hCNT-3, the most active compounds 39 and 50 behaved as 
outliers, which indicate a possibility of different binding site or binding mode compared 
to the other compounds. It may also be due to an inadequacy of the modeling methods. 
Some of the possible reasons for the outlier status are: i) different binding site or binding 
mode compared to the rest of the compounds, ii) inability to align correctly with the 
training set, iii) inaccurate activity data, iv) physiochemical properties falling far outside 
the range of the rest of the training set compounds, and v) other processes not accounted 
for such as metabolism or transport. 
 
The compounds belonging to the test set were selected to get a good R2 
predictivity. The prediction curves for both CoMFA and CoMSIA, as shown in Figures 
3.5 to 3.8, are the graphs of the predicted activity vs. actual activity. The graphs show a 
good scatter of compounds around the regression line, which indicates good fitting of the 
data. The predictive abilities of the models were evaluated against 9 and 10 test 
compounds for CoMFA and CoMSIA, respectively and the values are listed in Table 3.5 
were used to calculate the R2pred (correlation coefficient for predictive ability). From 
Table 3.6, it can be seen that the predictive ability of the CoMFA model is slightly better 
than the CoMSIA model.
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Figure 3.5:  Prediction curves for CoMFA and CoMSIA models for hCNT1   
                             inhibition 
                     
 
R2 = 0.8396
3.2
3.7
4.2
4.7
5.2
5.7
3.6 4.1 4.6 5.1 5.6
ACTUAL ACTIVITY
P
RE
DI
CT
E
D
 A
CT
IV
IT
Y
    
                              CoMFA 
R2 = 0.8626
3
3.5
4
4.5
5
5.5
6
3.5 4 4.5 5 5.5 6
ACTUAL ACTIVITY
PR
ED
IC
TE
D 
A
CT
IV
IT
Y
  
CoMSIA 
 
Figure 3.6:  Prediction curves for CoMFA and CoMSIA models for hCNT2  
                             inhibition 
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Figure 3.7:  Prediction curves for CoMFA training set and test set for hCNT3 
                           inhibition 
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Figure 3.8:  Prediction curves for CoMSIA training set and test set for hCNT3 
              inhibition 
 
 
 
 
 
 37
Table 3.5: Residuals of predictions of test set by CoMFA and CoMSIA models for hCNT3 inhibition 
 
Compound 
number 
Actual 
pKi 
Predicted 
CoMFA pKi 
CoMFA 
Residuals 
Compound 
number 
Actual 
pKi 
Predicted 
CoMSIA pKi 
CoMSIA 
Residuals 
2 4.32 4.63 -0.31 12 5.39 5.14 0.24 
3 5.01 5.12 -0.10 22 3.82 4.63 -0.80 a 
10 4.81 4.92 -0.10 33 4.86 4.70 0.15 
32 4.56 4.77 -0.20 48 4.59 5.03 -0.43 
49 5.21 5.12 -0.08 56 4.52 4.64 -0.12 
54 4.56 4.82 -0.26 61 4.56 4.48 0.07 
64 4.58 4.51 0.07 68 4.47 4.32 0.15 
70 4.76 4.68 0.08 75 4.65 4.60 0.05 
81 4.65 4.50 0.14 8 4.72 4.54 0.18 
----- ----- ----- ----- 84 6.05 5.34 0.71 a 
 
aThe residual values greater than 0.5 is responsible for the low predictivity of the respective models. 
 
 
Table 3.6: Predictive R2 values of test set by CoMFA and CoMSIA models for hCNT3 inhibition 
 
 hCNT3  CoMFA hCNT3  CoMSIA 
 
R2 predictivity 
 
0.596 
 
0.569 
 
R2 predictivity =  Correlation coefficient for predictive ability 
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3.8  PLS Contour Maps 
 
Contour maps were generated by plotting the coefficients from CoMFA and 
CoMSIA QSAR models, which indicate regions in 3D space around the molecules where 
changes in the particular physicochemical properties are predicted to increase or decrease 
potency. The steric and electrostatic contours for CoMFA and CoMSIA models, and 
hydrophobic and hydrogen bond contours for the CoMSIA model for hCNT transporter 
inhibition, projected onto compound 49, are shown in Figures 3.9 to 3.11.  
 
Steric and electrostatic contours: Green contours indicate sterically favored 
regions whereas yellow contours denote sterically unfavorable regions. Blue contours 
identify regions that favor electropositive substituents and red regions favor 
electronegative substituents. 
 
Hydrophobic, hydrogen bond donor and acceptor contours: Yellow contours 
indicate regions where hydrophobic groups are favored whereas white contours denote 
regions that disfavor hydrophobic groups. For the CNT1 CoMSIA model, color coding 
for a hydrophobic substituent favored region is orange. The cyan and purple contours 
indicate favorable and unfavorable regions for hydrogen bond donors, respectively. The 
magenta and red contours identify favorable and unfavorable positions for hydrogen bond 
acceptors, respectively. 
 
 
3.8.1  PLS Contour Interpretation for CNT1 CoMFA 
 
 A distinct green contour near the 2-position phenyl ring indicates that sterically 
bulky substituents are favoured in this region. Red contours around the phenyl ring at the 
5’-position indicate a favorable region for electronegative substituents. A red contour 
near position 8 also shows another region that favors electronegative substituents. A large 
blue contour near the 3’- of 2-position phenyl ring shows region that favors 
electropositive groups and small blue contours near 3- and 4- positions of the flavone 
indicate a region which can tolerate electropositive substituents (Figure 3.9A). 
 
 
3.8.2  PLS Contour Interpretation for CNT1 CoMSIA 
 
A green contour covering the 2-position phenyl ring indicates sterically favored 
region. Also, an orange contour covering the same part of molecule depicts a region that 
favors hydrophobic groups. The 4’-position is occupied by a blue contour suggesting an 
electrostatically favored part. A white contour near the 5’- and 6’- positions map 
hydrophobically unfavorable regions. A large yellow contour near the 3-position 
surrounding a blue contour in it indicates that this region is unfavorable for hydrophobic 
substituents and the blue contour suggests that electropositive groups are favored here  
(Figure 3.9B). 
                                                           
 39
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9:  PLS contours from CoMFA steric and electrostatic (A) and CoMSIA steric, electrostatic and hydrophobic (B)                    
                     descriptors for hCNT1 inhibition 
 
 
 
 
 
 
(A) 
 
 
(B) 
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(A)            (B)           (C) 
 
Figure 3.10:  PLS contours from CoMFA steric and electrostatic (A), CoMSIA steric and electrostatic (B) and CoMSIA 
                             hydrophobic and hydrogen bond donor and acceptor (C) descriptors for hCNT2 inhibition 
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(A)       (B)            (C) 
 
Figure 3.11:  PLS contours from CoMFA steric and electrostatic (A), CoMSIA steric and electrostatic (B) and CoMSIA 
                             hydrophobic and hydrogen bond donor and acceptor (C) descriptors for hCNT3 inhibition 
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 3.8.3  PLS Contour Interpretation for CNT2 CoMFA 
 
The 2-position phenyl ring is sterically favored as shown by the presence of two 
green contours around it. Position 8 is strongly recommended for electronegative 
substituents due to the presence of a large red contour. Positions 5 and 6 are favorable 
towards electropositive substituents, whereas position 4 is favorable for electronegative 
substituents. The region between positions 6 and 7, and the region around position 3 are 
strictly unfavorable for sterically bulky groups (Figure 3.10A). 
 
 
3.8.4  PLS Contour Interpretation for CNT2 CoMSIA 
 
 A large green contour over the 2-position phenyl ring indicates a sterically 
favored region. A red contour at the same position shows that an electronegative group is 
favored as well. Position 3 shows a blue contour covering a yellow one indicating that it s 
an electropositive favored region but no tolerence for sterically bulky groups. A red 
contour at the 8- and blue at 6-positions indicate electrostatically disfavored and favored 
regions, respectively (Figure 3.10B). 
 
A large yellow contour at the 2’ and 3’ positions of the 2-phenyl ring indicates a 
strong propensity for hydrophobic groups. A white contour near position 3 shows a part 
the of molecule that disfavors hydrophobic groups. A cyan contour near position 7 and a 
magenta near position 8 show regions favored for H-bond donor and H-bond acceptor 
groups, respectively. The occurance of red and purple contours near positions 5 and 6 
denote that this part of the molecule is neither favored for H-bond donor nor for acceptor 
groups (Figure 3.10C). 
 
 
3.8.5  PLS Contour Interpretation for CNT3 CoMFA 
 
 A green contour overlapped by a blue one near the 3’-position of the 2-phenyl 
ring indicates that the position favors sterically bulky and electropositive groups. Two 
distinct red contours near the 2’- and 5’- positions show positions suitable for 
electronegative groups. The blue contour at position 7 shows that electropositive groups 
are predicted to increase activity at that location. The same position is partly favoured 
and and partly disfavored for sterically bulky groups as well (Figure 3.11A). 
 
 
3.8.6  PLS Contour Interpretation for CNT3 CoMSIA 
 
The red contours between positions 5 and 6, at position 8 and near the 5’ and 6’ 
positions indicate electronegative substituent favored regions. A large green contour over 
the 2-phenyl ring and the yellow contour near position 3 indicate sterically favored and 
disfavored regions, respectively. Both the 3- and 3’- positions are prefer electropositive 
substituents (Figure 3.11B). 
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The yellow contours at the positions 2’ and 5’ signify favorable positions for 
hydrophobic groups. A hydrophobic substituent disfavored region at position 3 is 
indicated by the white contour. A cyan contour at position 7 shows a strong propensity 
for H-bond donor property; and the red contour at position 4 indicates an unfavorable 
position for H-bond acceptors. Purple and red contours near positions 4’ and 5’ indicate 
no tolerance for both H-bond donor or acceptor. Magenta contours near positions 2’ and 
8 indicate region favorable for H-bond acceptors (Figure 3.11C). 
 
In general, the active sites of the transporters can be outlined with the help of the 
isopleths obtained from 3D-QSAR analyses. For all the CNTs, (i) position 2 should be 
occupied by sterically bulky and a hydrophobic group to obtain compounds with 
increased activity, (ii) positions 7 and 8 should be substituted with H-bond donor and H-
bond acceptor groups, respectively (iii) position 3 is unfavorable to hydrophobic and 
bulky substituents, (iv) positions 2’ and 5’ favor electronegative groups and (v) position 3 
favors electropositive, whereas position 4 favors electronegative groups.  
 
The differentiating features for these three  CNTs are, 1) CNT1 can tolerate more 
sterically bulky group compared to the other two CNTs, 2) activity is significantly 
influenced by the presence or absence of H-bond donor and acceptor at positions 7 and 8 
for CNT2 and CNT3 inhibition, 3) substitutions at positions 5 and 6 do not significantly 
influence CNT1 inhibition but the inhibitory activity on CNT2 and CNT3 can be 
modified by the presence of appropriate electrostatic modifying functional groups as 
shown by different electrostatic contours. 
 
 
3.9 Activity Prediction of In silico Designed Compounds Using 3D-QSAR Models     
       for hCNT3 
 
One of the best uses of 3D-QSAR models is their use for prediction of designed 
molecules which have not been synthesized or tested yet for the desired biological 
activity. The models derived for hCNT3 inhibition were validated for predictive ability 
by dividing the data set into training and test sets and the highest R2-predictivity was ~0.6 
for CoMFA compared to 0.569 for CoMSIA. These models were used to predict the 
activities of 58 in silico designed molecules which are listed in Table 3.7. The predicted 
activities were compared with the potent inhibitors compound, 50 (pKi = 6.237) and 
compound 84 (pKi= 6.056). Some compounds from Table 3.7 such as Pred 2, Pred 16, 
Pred 19, Pred 20 and Pred 21 showed the highest predicted activities and it was 
distinctly noticed that these compounds have -NH2 substitution as the R3 group, 
suggesting the importance of H-bond donor at this position (Figure 3.12). These 
compounds were searched for their availability using SciFinder search module and it was 
found that none of these good predicted compounds are available commercially yet, in 
turn suggesting their novelty. These compounds can be synthesized and biologically 
evaluated.   
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Table 3.7: Predicted activities for in silico designed compounds for hCNT3-inhhibition 
 
 
 
 
 
          
Compound X R2 R3 Y R5 R6 R7 R8 hCNT3 pKi (µM) 
         CoMFA CoMSIA
           
Pred 1 NH 3-hydroxyphenyl N CH2  H H OH OH 5.0894 5.4002 
Pred 2 O 3-hydroxyphenyl NH2 C=O H H OH OH 5.2408 5.9004 
Pred 3 O 3-hydroxyphenyl CN C=O H H OH OH 5.4583 5.5355 
Pred 4 O 3-hydroxyphenyl H C=O H H OH Acetyl 5.2366 5.2125 
Pred 5 O 3-hydroxyphenyl H C=O H H OH N3 5.3650 5.1107 
Pred 6 O 3-hydroxyphenyl H C=O H H OH Br 5.2089 4.9560 
Pred 7 O 3-hydroxyphenyl H C=O H H OH Cl 5.2617 5.0409 
Pred 8 O 3-hydroxyphenyl H C=O H H OH CN 5.2691 5.1720 
Pred 9 O 3-hydroxyphenyl H C=O H H OH F 5.1534 5.0479 
Pred 10 O 3-hydroxyphenyl H C=O H H OH Formyl 5.2695 5.0802 
Pred 11 O 3-hydroxyphenyl H C=O H H OH I 5.1486 4.8534 
Pred 12 O 3-hydroxyphenyl H C=O H H OH NO2 5.5612 5.5916 
Pred 13 O 3-hydroxyphenyl H CH2 H H OH OH 5.5351 5.5770 
Pred 14 O 3-hydroxyphenyl H CH2 H CH3 OH OH 5.5928 5.5767 
Pred 15 O 3-hydroxyphenyl H C=O H Tetrahydro 
isoquinolino 
H 5.1472 5.3560 
Pred 16 O 3-hydroxyphenyl NH2 CH2 H H OH OH 5.5568 6.0750 
Pred 17 O 3-hydroxyphenyl H C=O H H NH2 OH 5.0259 5.5197 
Pred 18 O 3-hydroxyphenyl H CH2 H OCH3 OH OH 5.4888 5.6436 
Y
X
A B
R8
R7
R6
R5
R3
R2
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Table 3.7: (continued) 
          
Compound X R2 R3 Y R5 R6 R7 R8 hCNT3 pKi (µM) 
         CoMFA CoMSIA
           
Pred 19 O 3-hydroxyphenyl NH2 CH2 H CN OH OH 5.5568 6.1241 
Pred 20 O 3-hydroxyphenyl NH2 CH2 H CN OH NO2 5.9676 6.3450 
Pred 21 O Tetrazoyl  NH2 CH2 H CN OH NO2 5.2610 5.8926 
Pred 22 O 3-hydroxyphenyl H 3 membered
B ring 
H H OH OH 5.2425 5.3099 
Pred 23 NH 3-hydroxyphenyl H 3 membered
B ring  
H H OH OH 5.0969 5.5006 
Pred 24 NH 3-hydroxyphenyl H C=O H H OH OH 5.1599 5.4527 
Pred 25 O 3-hydroxyphenyl N C=O H H OH OH 5.1265 5.3518 
Pred 26 CH2 3,4,5-trimethoxyphenyl H CH2 H H OH H 5.4952 4.8389 
Pred 27 CH2 3,4,5-trimethoxyphenyl OH C=O H H OH H 5.3633 4.9562 
Pred 28 CH2 3,4,5-trimethoxyphenyl OH CH2 H H OH H 5.6982 5.1398 
Pred 29 NH 3,4,5-trimethoxyphenyl OH C=O H H OH H 5.2473 5.1803 
Pred 30 NH 3,4,5-trimethoxyphenyl NH2 C=O H H OH H 5.2020 5.2744 
Pred 31 O 2-NH2,3,4,5-trimethoxyphenyl OH C=O H H OH H 5.3347 5.2910 
Pred 32 O 2-OH,3,4,5-trimethoxyphenyl OH C=O H H OH H 5.2122 5.1918 
Pred 33 O 3,4,5-trimethoxyphenyl OCH3 C=O H H OH H 5.0896 5.1326 
Pred 34 O 3,4,5-trimethoxyphenyl OH CH2 H H OH H 5.3347 5.2425 
Pred 35 O 3,4,5-trimethoxyphenyl OH C=O OH H OH H 5.1796 5.1052 
Pred 36 O 3,4,5-trimethoxyphenyl OH C=O H CN OH H 4.9763 5.1815 
Pred 37 O 3,4,5-trimethoxyphenyl OH C=O H NH2 OH H 5.2424 5.0991 
Pred 38 O 3,4,5-trimethoxyphenyl OH C=O H OH OH H 5.2910 5.1160 
Pred 39 O 3,4,5-trimethoxyphenyl OH C=O H H CN H 5.3218 4.8213 
Pred 40 O 3,4,5-trimethoxyphenyl OH C=O H H CN NH2 5.2755 5.2923 
Pred 41 O 3,4,5-trimethoxyphenyl OH C=O H H SH H 5.1556 4.8635 
Pred 42 O 3,4,5-trimethoxyphenyl OH C=O H H N3 H 5.0955 4.8090 
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Table 3.7: (continued) 
 
Compound X R2 R3 Y R5 R6 R7 R8 hCNT3 pKi (µM) 
         CoMFA CoMSIA
           
Pred 43 O 3,4,5-trimethoxyphenyl OH C=O H H NH2 H 5.1002 5.2004 
Pred 44 O 3,4,5-trimethoxyphenyl OH C=O H H NO2 H 5.6695 4.7746 
Pred 45 O 3,4,5-trimethoxyphenyl H C=O H H OH H 5.0245 4.7465 
Pred 46 O 3,4,5-triethoxyphenyl OH C=O H H OH H 5.3961 4.9736 
Pred 47 CH2 3,4,5-trimethoxyphenyl OCH3 CH2 OCH3 OCH3 OCH3 H 4.1784 4.9407 
Pred 48 O 3,4-methylenedioxy-5-methoxy
phenyl 
OH C=O H H OH H 4.1996 5.0094 
Pred 49 O 3,4,5-trimethoxyphenyl OCH3 C=O OCH3 OCH3 OCH3 H 3.8809 4.7287 
Pred 50  O 3,4,5-trimethoxyphenyl H C=O OCH3 OCH3 OCH3 H 4.0213 4.6782 
Pred 51 O 3,4,5-trimethoxyphenyl OH C=O OCH3 OCH3 OCH3 H 3.9378 4.9402 
Pred 52 O 3,4,5-trimethoxyphenyl H C=O H H OCH3 OCH3 4.7539 4.4927 
Pred 53 O Phenyl NH2 C=O H OH OCH3 H 4.3038 5.008 
Pred 54 O Phenyl OH C=O H OH OCH3 H 4.4621 4.7291 
Pred 55 O 4-hydroxy phenyl NH2 C=O H H OH OH 4.6009 5.0547 
Pred 56 O 4-hydroxy phenyl OH C=O H H OH OH 5.1213 5.2011 
Pred 57 O 3,4,5-trihydroxyphenyl NH2 C=O H H OH H 4.8295 5.6005 
Compound 
XI 
O 3,4,5-trimethoxyphenyl ------ ------ H H OCH3 OCH3 4.7762 4.5118 
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Figure 3.12: In silico compounds with high predicted hCNT3 inhibitory activity 
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3.10  Discussion 
 
The highlights of the SAR are: 1) hCNT3 is the most sensitive to inhibition by 
flavones followed by hCNT2 and then hCNT1. 2) Compound 49 is the most active 
flavone against CNT1 and CNT2 (IC50 values of 11.75 μM and 1.66 μM, respectively), 
whereas, compound 39 is most active for CNT3 (IC50 of 0.57 μM). But, compound 39 
does not obey the general trend followed by other active flavones, i.e. the presence of 7-
OH. Thus, it is thought to possibly act via a different binding mode. 3) The other highly 
active inhibitors for CNT3 are compounds 50 (IC50 of 0.68 μM) and 84 (IC50 of 1.04 
xμM). 4) In general, the 7,8-dihydroxy moiety is a key structural feature particularly for 
inhibition of hCNT2 and hCNT3 by flavones (compounds 13, 49, 50, 51, 57). 5) 3’-
Hydroxy and 4’-hydroxy substitutions are also favorable structural features for higher 
inhibitory activity (compounds 49, 50). 6) Methoxy substitution on the 2-phenyl ring is 
detrimental for all three hCNTs (compounds 16, 18-33, 35). 7) The 7,8-dihydroxy 
substitution is much better than 7,8-dimethoxy substitution (compare compounds 13 and 
55).  8) Interestingly, 7,8-dihydroxy substitution in isoflavones does not improve activity 
(compounds 78-80, 82, 83). 9) Compounds with 3’,4’,5’-trihydroxy substitution are 
better inhibitors (compounds 72, 84, 85) than those with 3’,4’,5’-trimethoxy substitution 
(compare with compound 35). 10) Compounds 9, 48, and 81 with 6,7-dihydroxy 
substitution are slightly more selective for hCNT1. 11) All of the chalcones are only 
moderately active against hCNT3 (compounds 43-47), but inactive against hCNT1 or 
hCNT2. 12) Compound 49 is the most selective compound against hCNT2 (7.07 folds 
and 4.32 folds compared to hCNT1 and hCNT3, respectively); other selective compounds 
are compounds 54, 57 and 85 (20.69 folds, 4.08 folds and 2.93 folds compared to hCNT1 
and 2.90 folds, 2.34 folds and 1.47 folds compared to hCNT3 for compounds 54, 57 and 
85,  respectively). 13) Compounds 12 and 83 are selective inhibitors of hCNT3 (7.54 
folds and 17.17 folds compared to their inhibition of hCNT1 and 5.14 folds and 6.62 
folds compared to hCNT2, for compounds 12 and 83, respectively). 14)  
Naphthoflavones containing 3’-OH or 3’,4’-dihydroxyphenyl moiety (compounds 62, 66, 
67) are more active than those having 2’-OH or 4’-OH substitution (compounds 64, 65, 
68, 69). 15) In general, 3’,4’-dihydroxy substitution is favored in the naphthoflavone 
class,  but compound 63 is an exception, which has 3’,4’-dimethoxy substitution. 
  
Taking into consideration, the contributions made by different descriptors for all 
the CNTs, it can be said that, in the case of CoMFA, the steric descriptor contributes to 
greater extent than the electrostatic descriptor for hCNT1 and hCNT2, whereas for 
hCNT3, the reverse is true. For the CoMSIA analyses, the electrostatic descriptor 
contributes the most among all the CoMSIA descriptors for all the transporters. The 
hydrogen bond donor descriptor is the next most important descriptor in the case of 
hCNT2 and hCNT3 followed by hydrophobic descriptors and then the H-bond acceptor 
descriptor.  
 
 The QSAR models derived for hCNT3 were utilized for prediction of in silico 
designed compounds some of which showed high predicted activities. These compounds 
(Pred 2, Pred 16, Pred 19, Pred 20, Pred 21) can be acquired and assayed to examine 
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the validity of these predictions and the additional information can be utilized to explore 
more molecules for the possibility of finding better hCNT3 inhibitors. 
 
 
3.11  Conclusion 
 
In this study, an attempt has been made to rationalize the binding data of new 
selective inhibitors of all the three cloned hCNT transporters and to understand the 
structural features important for selective and potent inhibitory activity at each 
transporter. The obtained CoMFA and CoMSIA contours can be used to assist the design 
of selective compounds. These models correlate structural features with inhibitory 
activities against CNTs and bring valuable information regarding the relevant 
characteristics of flavonoids tested and the active sites; but this information might not 
hold true for flavones with more diverse functionalities. The new compounds designed 
and predicted in silico to have high activity may be useful in finding new leads for 
hCNT3 inhibition.  
 
 
3.12  Experimental Section: [3H]-Uridine Uptake Assay 
 
The ability of the compounds to inhibit uptake of nucleosides CNTs was 
determined by studying the inhibition of uptake of radiolabeled uridine. Uptake 
experiments were performed on a nucleoside transporter deficient, PK15NTD cell line, 
stably expressing the cloned hCNT 1, 2 or 3 nucleoside transporter. Cells were 
maintained in Eagles minimum essential medium/Earles’s balanced salt solution (1:1) 
with 0.1mM non-essential amino acids, 1mM sodium pyruvate, 5% Fetal bovine serum, 
penicillin/streptomycin (50,000 units/litre, 50 mg/litre) at 37° C with 5% CO2 and 95% 
air. The Na buffer was HEPES Ringers solution containing (in mM): 135.0 NaCl, 5.0 
KCl, 3.3 NaH2PO4, 0.8 Na2HPO4, 1.0 CaCl2, 1.0 MgCl2, 10.0 glucose, and 5.0 HEPES 
(pH 7.4). Na free buffer contained (in mM): 140.0 N-methyl-D-glucamine (NMDG), 5.0 
HEPES, 5.0 KH2PO4, 1.0 CaCl2, 1.0 MgCl2, and 10.0 glucose (pH 7.4). The cells were 
seeded into a 48 well plate and grown until confluent. The cells were washed three times 
in Na-free buffer solution followed by the addition of varying concentrations of the 
inhibitors (1 nM – 200 μM) and [3H] uridine (0.2 μM). The [3H] uridine uptake was 
measured for 2 minutes. Following a two-minute exposure the action of radiolabelled 
uridine was terminated by rapidly washing the cells thrice with ice cold PBS (pH 7.4). 
Cells were solubilized overnight in 300 μl 5% Triton X-100, and radioactivity was 
measured by β-counter. The PRISM program was used (GraphPad, San Diego, CA) to 
derive concentration dependent curves to obtain IC50 values which were finally used to 
calculate inhibition constants (Ki). 
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Chapter 4: Biological Evaluation and 3D-QSAR Studies of Flavones Analogs for 
Human Equilibrative Nucleoside Transporter Inhibition 
 
 
4.1  Introduction 
  
In this chapter, QSAR studies have been applied to the modeling of the ENT1 and 
ENT2 inhibitory activities of flavonoids. In our current work, we carried out 3D-QSAR 
studies to establish correlations between structural properties of 95 flavones, chalcones 
and analogous compounds such as coumarins and a quinoxaline derivative and their 
inhibitory activities against ENT1 and ENT2. 3D-QSAR analyses were performed using 
comparative molecular field analysis (CoMFA) and comparative molecular similarity 
indices analysis (CoMSIA).  The models derived were used to predict the activities of 
designed flavones. Based on the SAR, a new lead compound XI was designed; but a 
mixture of compounds XII and XIII was obtained after an attempted synthesis of this 
compound. The mixture was evaluated as such, against hENT1, hENT2 and hCNT3 
transporters. 
 
 
4.2  Biological Evaluation: Uridine Uptake Assay 
 
The procedure followed for the assay is same as that mention in Chapter 3. The 
cell line that was used for the study is the nucleoside transporter deficient PK15NTD cell 
line stably transfected with cDNA of hENT1 or hENT2. The amount of radiolabeled 
uridine present intracellularly following a five or two minutes exposure of [3H]-uridine to 
ENT1 (0.3 μM) or ENT2 (0.2 μM), respectively, is determined in the absence and 
presence of varying concentrations of an inhibitor (1 nM – 200 μM). Details of the [3H] 
uridine uptake assay are provided in the experimental section in Chapter 3. All 
compounds used in the study were first screened at a concentration of 10 μM. Only those 
compounds showing more than 50% inhibition at 10 μM were further tested for IC50 
determination. Figure 4.1 shows the comparison graph of ENT and ENT2 inhibition by 
the compounds. S6-(4-Nitrobenzyl) mercaptopurine riboside (NBMPR, V) and 
dipyridamole (VI) were used as standards to compare the inhibitory activities of the 
compounds. 
 
The results obtained from [3H]-nucleoside uptake assays were entered into the 
PRISM program (GraphPad, San Diego, CA) to plot concentration-dependent inhibition 
curves (Figures 4.2 and 4.3). From these curves, the IC50 values (Table 4.1) were 
computed and used to calculate inhibition constant (Ki) values using Equation 4.1. 
 
                                   Ki = IC50/(1+[L]/KL)                                                  (Eq. 4.1) 
 
where, [L] and KL are the concentration and the Km value of [3H] uridine, respectively. 
The Ki values were used to compare the abilities of the compounds to inhibit [3H]-uridine 
uptake.   
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Figure 4.1:  Comparison graph of % of inhibition at 10 μM 
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Figure 4.2:  IC50 curves of compounds in study for ENT1 inhibition 
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Figure 4.3:  IC50 curves of compounds in study for ENT2 inhibition 
 
 
 
 54
Table 4.1: Compounds evaluated for ENT inhibition with IC50 values 
 
O
O
R2
Flavone (A) Chalcone (B)
R3
R5
R6
R7
R8
O R2
R3
R5
R6
R7
R8
N
N R2
R3
R5
R6
R7
R8
R4
O O
R3
R5
R6
R7
R8
R4O
R2
R5
R6
R7
R8
Coumarin (C) (D) Quinoxaline (E)  
 
Compound Type R2 R3 R4 R5 R6 R7 R8 hENT1 
IC50 (µM) 
hENT2 
IC50 (µM) 
SIa 
            
V - - - - - - - - 0.0006  ±  
0.0004 
0.87  ±  0.01 - 
VI - - - - - - - - 0.015  ±  0.001 0.32  ±  0.03 - 
1 A 4-bromophenyl H C=O H Cl CH3 H - -   - 
2 A 4-hydroxyphenyl OH C=O H H H H - - - 
3 A 3,4-dihydroxyphenyl H C=O H H OH H 14.08  ±  2.63 1.81  ±  0.46 7.77 
4 A Phenyl OH C=O OH H H H 28.45  ±  2.78 28.19  ±  4.23 1.00 
5 A Phenyl OH C=O H OH H H 22.18  ±  1.78  6.66  ±  2.02 3.33 
6 A Phenyl OH C=O H H OH H 50.31  ±  4.02 - - 
8 A 4-hydroxyphenyl H C=O H OH H H 12.59  ±  2.33 - - 
9 A Phenyl H C=O H OH OH H 5.58  ±  1.03 8.83  ±  1.37 0.63 
10 A 2-hydroxyphenyl H C=O H H OH H 20.10  ±  4.18 27.30  ±  17.60 0.73 
11 A 3-hydroxyphenyl H C=O H H OH H 4.84  ±  0.24 11.96  ±  2.21 0.40 
12 A 4-hydroxyphenyl H C=O H H OH H 4.00  ±  0.51 7.20  ±  1.36 0.55 
13 A Phenyl H C=O H H OH OH 8.72  ±  1.44 -   - 
14 A 4-hydroxyphenyl H C=O OH H OCH3 H 17.04  ±  1.79 14.01  ±  10.26 1.21 
15 A Phenyl H C=O OH OH OCH3 H 16.72  ±  5.09 8.49  ±  0.53 1.96 
16 A 3,4,5-trimethoxyphenyl OH C=O H H OH H 1.02  ±  0.09 2.81  ±  0.71 0.36 
17 A 3-hydroxy-4-
methoxyphenyl 
H C=O OH OCH3 OCH3 H 7.27  ±  3.18 14.76  ±  1.79 0.49 
18 A 2,3-dimethoxyphenyl H C=O H H H H 16.87  ±  7.27 13.58  ±  2.73 1.27 
19 A 4-methoxyphenyl OCH3 C=O H H H H 2.98  ±  1.17 9.98  ±  2.69 0.29 
20 A 3,4-dimethoxyphenyl H C=O H H H H 4.98  ±  1.96 10.77  ±  4.71 0.46 
22 A Phenyl H C=O H OCH3 OCH3 H 1.62  ±  0.77 7.65  ±  2.21 0.14 
23 A 3,4-dimethoxyphenyl OH C=O H H H H 112.31  ±  7.97 11.45  ±  2.09 9.80 
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Table 4.1: (continued) 
 
Compound Type  R2  R3 R4 R5 R6 R7 R8 hENT1   
IC50 (µM) 
hENT2 
IC50 (µM) 
SIa 
            
24 A 2,3-dimethoxyphenyl OH C=O H H H H 24.47  ±  5.71 22.42  ±  5.91 1.09 
25 A 2,4-dimethoxyphenyl  C=O H H H H -  27.24  ±  9.62 - 
26 A 2-methoxyphenyl OH C=O H OCH3 H H 76.30  ±  3.07 -   - 
27 A 3-methoxyphenyl OH C=O H OCH3 H H 137.55  ±  16.70 22.66  ±  5.09 6.07 
28 A 4-methoxyphenyl OH C=O H OCH3 H H -  - - 
30 A 3-methoxyphenyl OH C=O H H OCH3 H 104.33  ±  12.02 11.44  ±  1.51 9.11 
31 A 2,4-dimethoxyphenyl OH C=O H CH3 H H - 26.09  ±  6.56 - 
32 A 3,4-dimethoxyphenyl OH C=O H CH3 H H - -   - 
33 A 3,4-dimethoxyphenyl H C=O OH OCH3 OCH3 H - - - 
34 A 3,4-dihydroxyphenyl OH C=O H H OH H 28.92  ±  1.26 8.11  ±  1.90 3.56 
35 A 3,4,5-trimethoxyphenyl H C=O OH OCH3 OCH3 OCH3 4.65  ±  0.82 1.77  ±  0.64 2.62 
36 A 3,4,-dihydroxyphenyl OH C=O OH H OH OH - -   - 
37 A 3,4,-dihydroxyphenyl OH C=O OH H OH OGlu - - - 
38 A 3,4,5-trimethoxyphenyl H C=O OCH3 OCH3 OCH3 H - - - 
39 A Phenyl H C=O H OH OCH3 H - - - 
40 A 4-methoxyphenyl H C=O H H OH H 32.83  ±  4.39 - - 
41 A 3,4,5-trimethoxyphenyl OH C=O H H OCH3 H 19.05  ±  0.91 9.51  ±  2.14 2.00 
42 A 3,4,5-trimethoxyphenyl OH C=O H H H H 7.17  ±  1.51 12.49  ±  1.97 0.57 
43 B 2-hydroxy-4-
methoxyphenyl 
- C=O H OCH3 H H 5.71  ±  0.45 -   - 
44 B 3,4-Dimethoxy-2-
hydroxyphenyl 
- C=O H H H H 3.64  ±  0.39 9.98  ±  1.34 0.36 
45 B 2-hydroxy-4-
methoxyphenyl 
- C=O H H OCH3 H 101.93  ±  6.76 16.82  ±  4.38 6.06 
46 B 2-hydroxy-5-
methylphenyl 
- C=O OCH3 H OCH3 H 9.71  ±  0.23 - - 
47 B 2-hydroxy-5-
methylphenyl 
- C=O OCH3 H H OCH3 11.85  ±  0.62 - - 
48 A 2-phenyl H C=O OH OH OH H 7.01  ±  1.33 8.22  ± 2.09 0.85 
49 A 3-hydroxyphenyl H C=O H H OH OH - - - 
50 A 4-hydroxyphenyl H C=O H H OH OH 10.61  ±  0.49 17.79  ±  3.57 0.59 
51 A 3,4-dihydroxyphenyl H C=O H H OH OH 13.71  ±  1.12 63.94  ±  11.05 0.21 
52 A Phenyl H C=O OH OH H H 14.88  ±  1.43 - - 
53 A 3-hydroxyphenyl H C=O H H OH H 20.04  ±  0.37 7.23  ±  1.89 2.77 
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Table 4.1: (continued) 
 
Compound Type R2 R3 R4 R5 R6 R7 R8 hENT1 
IC50 (µM) 
hENT2 
IC50 (µM) 
SIa 
            
54 A 3,4-dihydroxyphenyl H C=O H H 
 
20.28  ±  0.78 -  - 
55 A Phenyl H C=O H H OCH3 OCH3 6.24  ±   0.21 12.98  ±  1.86 0.48 
56 A Phenyl H C=O H H OCH3 OH 5.68  ±  0.36 41.71  ±  2.09 0.13 
57 A 2-hydroxyphenyl H C=O H H OH OH 7.40  ±  0.24 - - 
58 A H 4-chloro 
phenyl 
C=O H H OH CH3 -   - - 
59 A H phenyl  C=O H H OH CH3 - - - 
60 A Phenyl H C=O 
 
H H - - - 
61 A Phenyl H  C=O H H 
 
15.36  ±  1.69 - - 
62 A 3,4-dihydroxyphenyl H C=O 
 
H H - - - 
63  A 3,4-dimethoxyphenyl H C=O H H 
 
2.65  ±  0.36 6.29  ±  0.87 0.42 
64 A 2-hydroxyphenyl H C=O H H 
 
- - - 
65 A 2-hydroxyphenyl H C=O 
 
H H - - - 
66 A 3-hydroxyphenyl H C=O H H  3.32  ±  0.26 50.82  ±  7.13 0.06 
67 A 3-hydroxyphenyl H C=O 
 
H H - 100.23  ±   10.19 - 
68 A 4-hydroxyphenyl H C=O H H 
 
- - - 
69 A 4-hydroxyphenyl H C=O 
 
H H - - - 
70 A 2-phenyl OCH3 C=O H H O  
- 129.59  ±  13.85 - 
71 A 4-methoxyphenyl H C=O H H 
 
32.71  ±  1.89 - - 
72 A 3,4,5-trihydroxyphenyl H C=O OH H OH H 6.46  ±  0.31 2.95  ±  0.79 2.18 
73 A 4-hydroxyphenyl H C=O H H OH OGlu - - - 
74 A H (1-phenyl-1H- 
pyrazol-4-yl) 
C=O H H OH OH - - - 
75 A Phenyl H C=O H H H H - - - 
77 A Phenyl H C=O H Cl Cl H - - - 
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Table 4.1: (continued) 
 
Compound Type R2 R3 R4 R5 R6 R7 R8 hENT1 
IC50 (µM) 
hENT2 
IC50 (µM) 
SIa 
            
78 A H 4-chloro 
Phenoxy 
C=O H H OH OH 10.08  ±  0.17 - - 
 
 
79 A H 4-Fluoro 
phenoxy 
C=O H H OH OH 11.38  ±  0.88 - - 
80 A Methyl phenyl C=O H H OH OH - 52.54  ± 3.66 - 
 
81 A H phenyl C=O H OH OH H - - - 
82 A H phenyl C=O H H OH OH - - - 
83 A H (4-CH3-2-
thiazoyl) 
C=O H H OH OH 10.80  ±  0.83 - - 
84 A 3,4,5-trihydroxyphenyl OH C=O H H OH H 26.81  ±   2.14 55.09  ±  8.62 0.48 
85 A 3,4,5-trihydroxyphenyl H C=O H H OH H - 16.14  ±  5.10 - 
86b - - -  - - - - - - - 
87c - - -  - - - - - - - 
88 C C=O H CH3 H H OH NO2 - - - 
89 C C=O 4’-methoxy 
phenyl 
CH2 H H OH H 25.07  ±  4.46 - - 
90 C C=O Phenyl CH2 H OCH3 H H - - - 
91 C C=O Phenyl CH2 H H OCH3 H 38.27  ±  0.13 49.43  ±  26.09 0.77 
92 C C=O H CH2 H  OH OH 83.79  ±  4.57 - - 
93 C C=O H CH-
phenyl 
H OH OCH3 H 5.92  ±  1.73 10.81  ±  1.41 0.54 
94 D 2-methyl  H H H H NH2 H 16.30  ±  0.59 - - 
95 C C=O Phenyl OH OH H OH H 2.24  ±  0.66 - - 
96 D 2-NH2 CN Pyridin 
-4-yl 
H H OH H 5.68  ±  0.46 1.77  ±  0.15 3.20 
97 D H Phenoxy H H H OH OH 46.47  ±  3.20 - - 
99 D 2-methyl 4’-nitro 
phenoxy 
H H H OCH3 CH3 9.08  ±  0.35 - - 
100 E 2-Phenyl H N H OCH3 OCH3 H 0.13  ±  0.03 4.89  ±  0.44 0.02 
                                                                 
aENT2 selectivity index (ENT1IC50 / ENT2IC50) 
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Table 4.1: (continued) 
 
C
O
OH
OH
OH
HO
OH
HO
                                                                            
Br Br
O
S O
O
O
OH OH
HO OH
   
bCompound 86 (2,3,4,3’,4’,5’-hexahydroxybenzophenone)                                       cCompound 87 (Bromopyrogallol red) 
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4.3  3-D QSAR Analyses 
 
Quantitative structure activity relationship (QSAR) is a statistical process by 
which the physicochemical properties and/or structural descriptors of a molecule are 
correlated with its biological activity. Classical QSAR techniques usually consider the 2D 
structures of the molecules. The orientation of various moieties on the molecule and their 
interrelationship with each other and with interaction sites on the receptor contribute to 
the biological activity. Hence, QSAR methods based on the 3D structures would provide 
more detailed information regarding the drug receptor interaction than 2D-QSAR 
methods. In this chapter, we report a comprehensive 3D-QSAR study on a series of 95 
flavones, chalcones and coumarin derivatives. 
 
 
 4.3.1  Materials and Methods 
 
The biological activity data obtained for the SAR study was used to carry out 3D-
QSAR analyses. The structures of the compounds and activity values (IC50 values) are 
shown in Table 4.1. The IC50 values were transformed into Ki and then to pKi values, 
which were used as the dependent variable in CoMFA143 and CoMSIA144 analyses. 
 
 
 4.3.2  Molecular Modeling 
 
Three-dimensional structure building and all modeling operations were performed 
using SYBYL 7.3 (Tripos Associates Inc.)145 running on a Silicon Graphics Octane 
workstation. MOPAC charges were assigned to all molecules. Energy minimization was 
performed using the Tripos force field with a distance dependent dielectric and the BFGS 
algorithm, with a convergence criterion of 0.01 kcal/(mole* Å). Compounds in the data 
set were aligned using the MATCH module in SYBYL. Reference atoms selected for 
alignment are shown in Figure 4.4, and molecular alignment is shown in Figure 4.5.  
 
 
4.3.3  CoMFA and CoMSIA Models 
 
3D-QSAR analyses were performed in a stepwise manner. The 95 compounds 
were aligned to the common alignment template. For deriving the CoMFA and CoMSIA 
descriptor fields, the molecules were placed in a three dimensional cubic lattice with a 
spacing of 2 Å, and extending 4 Å units beyond the aligned molecules in all directions. 
CoMFA descriptors were calculated using an sp3 carbon probe atom with a van der Waals 
radius of 1.52 Å and a charge of +1 with a distance dependent dielectric to generate steric 
(Lennard-Jones 6-12 potential) field energies and electrostatic (Coulombic potential) 
fields with a distance-dependent dielectric at each lattice point. An energy cutoff of 30 
kcal/mole was applied. The CoMFA steric and electrostatic fields were scaled by the 
CoMFA-STD method in SYBYL. CoMSIA similarity index descriptors were calculated 
using a similar lattice box as in CoMFA. CoMSIA similarity index descriptors were  
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Figure 4.4:  Atoms used in MATCH alignment shown in bold face 
 
 
 
 
 
 
Figure 4.5:  Atom-by-atom superposition used for 3D-QSAR analysis 
 
For atom colors, red indicates oxygen, yellow refers to sulfur, white indicates carbon, 
green indicates fluorine or chlorine and cyan indicates hydrogen. 
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derived according to Klebe et al.144 The CoMSIA descriptors, namely, steric, 
electrostatic, hydrophobic, hydrogen bond donor, and hydrogen bond acceptor, were 
generated using a sp3 carbon probe atom with +1 charge and a van der Waals radius of 
1.4 Å. The value of the attenuation factor (α) was set to 0.3. CoMSIA steric indices are 
related to the third power of the atomic radii, the electrostatic descriptors are derived 
from atomic partial charges, the hydrophobic fields are derived from atom-based 
parameters developed by Viswanadhan et al.146, and hydrogen bond donor and acceptor 
indices are obtained from a rule-based method based on experimental data.  
 
Using CoMFA and CoMSIA descriptors as independent variables and pKi values 
as dependent variables, partial least squares (PLS) regression analyses were carried out, 
using the QSAR module of the SYBYL package with default parameters. Leave-one-out 
(LOO) cross-validation was used to evaluate the predictive ability of the models. The 
cross-validated coefficient, q2, was calculated using Equation 4.2. 
                                 
(Ypredicted _Yactual)2
(Yobserved _Ymean)2
1 _ ΣΣq
2 =
 
 
where Ypredicted, Yactual, and Ymean are predicted, actual and mean values of the target 
property (pKi), respectively.  Σ(Ypredicted – Yactual)2 is the predictive sum of squares 
(PRESS). The optimum number of components used to derive the final regression models 
was the one that corresponds to the lowest PRESS value. In addition to the q2, the 
corresponding PRESS, the conventional correlation coefficient (r2) and its standard error 
(s) were also calculated.  
 
 
4.3.4  Results of 3D-QSAR Analyses 
 
CoMFA and CoMSIA 3D-QSAR studies were undertaken to determine the effects 
of steric, electrostatic, hydrophobic, and hydrogen bonding properties of the compounds 
on different hENT nucleoside transporter inhibitory activity, and to obtain reliable 
models for predicting the activity of compounds. The results obtained from PLS 
regression analysis, using CoMFA steric and electrostatic descriptors as independent 
variables are shown in Tables 4.2 and 4.3, respectively. Similarly, PLS statistics obtained 
from CoMSIA analysis are also shown in the same tables. The stability of the models was 
evaluated by performing group cross-validation (30 runs), and bootstrapping (20 runs). 
To eliminate the possibility of chance correlation, PLS analysis was carried out using 
scrambled activity data (20 runs) i.e. randomization was done. The results of these 
validations are shown in Table 4.4. CoMFA and CoMSIA coefficient contour maps were 
generated by interpolation of the pair-wise products between the PLS coefficients and the 
standard deviations of the corresponding CoMFA and CoMSIA descriptor values.  
 
 Both the CoMFA and CoMSIA models have fairly good cross validated q2 and 
non-validated r2 values as shown in Table 4.2. The non-validated r2 value of the CoMSIA 
model is similar to that of the CoMFA model of both transporters. However, if the q2 
(Eq. 4.2)
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Table 4.2: PLS statistics of CoMFA and CoMSIA 3D-QSAR models for ENT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
q2 = cross validated correlation coefficient; s = standard error; r2 = non-validated correlation coefficient; F = F-test value. 
 
   
  
 
Transporter Type 
 
hENT1 
 
hENT2 
 
 
PLS statistics 
 
CoMFA 
 
CoMSIA 
 
CoMFA 
 
CoMSIA 
 
q2(LOO) 0.585 0.523 0.510 0.565 
r2 0.937 0.928 0.870 0.957 
S 0.120 0.129 0.177 0.107 
F 92.36 75.386 51.875 96.971 
PLS components 6 6 4 6 
Total no. of compounds used 
for analysis 
61 45 
No. of outliers 12 14 5 8 
Outlier Compounds 10,19,27,30,35, 
41,45,51,54,96, 
97,100 
10,22,23,35,40,41,45,
54,71,91,95,96,97, 
100 
17,18,19, 
27,84 
17,19,22,27, 
51,53,84,85 
No. of compounds in training 
set 
44 42 36 33 
No. of compounds in test set 5 5 4 4 
Test set compounds 4,11,61,89,99 4,11,17,46,99 4,14,41,56 4,12,55,100 
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Table 4.3: Field contribution by CoMFA and CoMSIA descriptors for ENT 
 
Descriptor hENT1 hENT2 
 
 CoMFA CoMSIA CoMFA CoMSIA 
     
Steric 0.402 0.113 0.315 0.092 
Electrostatic 0.598 0.322 0.685 0.404 
Hydrophobic ----- 0.144 ----- 0.175 
Donor ----- 0.251 ----- 0.204 
Acceptor ----- 0.169 ----- 0.125 
 
 
Table 4.4: Results of group cross validation, randomization and bootstrapping for 
ENT 
 
Method hENT1 hENT2 
 
 CoMFA CoMSIA CoMFA CoMSIA 
 
Group validation q2  
(30 groups and 30 runs)  
0.556 ± 
0.019 
0.518 ± 
0.025 
0.507 ± 
0.056     
0.554 ± 
0.023 
     
Randomization  q2 (20 
runs) 
- 0.155  - 0.223  - 0.109  - 0.068  
     
Bootstrapping (20 runs) 
1. r2 
0.945 ± 
0.021 
0.956 ± 
0.012 
0.909 ± 
0.038  
0.978 ± 
0.013 
     
2. SD 0.110 ± 
0.063 
0.103 ± 
0.062 
0.149 ± 
0.087  
0.077 ± 
0.058 
 
q2 = cross validated correlation coefficient; r2 = non-validated correlation coefficient; SD 
= standard deviation. 
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values are compared, the hENT1 CoMFA and hENT2 CoMSIA models appear to be 
better than the remaining two models. Outliers were decided on the basis of q2 by the 
leave-one-out method to arrive at a value more than or equal to 0.5. Also, other methods 
such as factor analysis and region focusing were applied to obtain significant PLS 
statistics. From Table 4.2, it can be seen that some of the compounds are common 
outliers in all the four models. The possible reasons for compounds to be outliers are 
given in Chapter 3 such as, improper alignment, inappropriate activity data, metabolism, 
etc. Compounds belonging to the test set were picked selectively to cover a wide range of 
activity. The prediction curves for both CoMFA and CoMSIA, as shown in Figures 4.6, 
4.7, 4.8, and 4.9, are the graphs of the predicted activity vs. actual activity. All graphs 
show well-scattered compounds around the regression line, which indicates that the 
models are good. The predicted activities with residuals are shown in Table 4.5. 
 
The derived models were further evaluated by using them to predict the activities 
of external test compounds 101, 102, 104, 105, 113, 114 and 115, all of which belong to 
flavone class and were not used to derive the forementioned models. Table 4.6 shows 
their predited activities with residuals, while the R2predictivity for the models are listed in 
Table 4.7. The prediction curves are presented in Figures 4.10 and 4.11.  
 
   From Table 4.7, it can be seen that all models can predict fairly  well, and the 
predictive ability of the CoMFA model for ENT2 is the best. One  residual value in 
Tables 4.5 and 4.6 is more than 0.5 log in the CoMFA models of ENT1 and ENT2, 
respectively, which is the cause of the lower R2pred for those models. Since the number of 
compounds included in the test set is low, the R2pred  values are probably too optimistic. 
Similarly, the results from Table 4.7 can be summerized by stating that  all the models 
have fairly good predictive abilities for external test compounds, which signifies the 
importance and validity of models generated for future use in prediction of activities of 
various molecules belonging to the same or similar chemical class as the flavones. 
 
 
            4.3.5  PLS Contour Maps 
 
Contour maps were generated by plotting the coefficients from CoMFA and 
CoMSIA QSAR models, which indicate regions in 3D space around the molecules where 
changes in the particular physicochemical properties are predicted to increase or decrease 
potency. The steric and electrostatic contours for the CoMFA and CoMSIA models, and 
hydrophobic and hydrogen bond contours for the CoMSIA model for hENT transporter 
inhibition, projected onto compound 16, are shown in Figures 4.12 and 4.13, respectively. 
General color coding for the contour maps are as follows: 1) steric and electrostatic 
contours: green contours indicate sterically favored regions whereas the yellow contours 
denote sterically unfavorable regions. The blue contours identify regions that favor 
electropositive substituents and the red regions favor electronegative substituents.  
2) Hydrophobic, hydrogen bond donor and hydrogen bond acceptor contours: yellow 
contours indicate regions where hydrophobic groups are favored whereas the white 
contours denote regions that disfavor hydrophobic groups. The cyan and purple contours 
indicate favorable and unfavorable regions for hydrogen bond donors, respectively. The 
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Figure 4.6:  Predicted vs actual PKi graphs for CoMFA training set and test set for 
                       hENT1 inhibition 
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Figure 4.7:  Predicted vs actual PKi graphs for CoMSIA training set and test set for 
                      hENT1 inhibition                     
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Figure 4.8:  Predicted vs actual PKi graphs for CoMFA training set and test set for 
                       hENT2 inhibition     
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Figure 4.9:  Predicted vs actual PKi graphs for CoMSIA training set and test set for 
           hENT2 inhibition        
 
 
 67
Table 4.5: Residuals of predictions of internal test set by CoMFA and CoMSIA models for hENT1 and hENT2 inhibition 
 
         ENT1 
 
Compound   Actual    Predicted       CoMFA       Compound   Actual     Predicted        CoMSIA 
number pKi    CoMFA pKi      Residuals       number         pKi     CoMSIA pKi     Residuals 
 
61          4.81 5.28          -0.46           4 4.54       4.14       0.39 
89          4.60 4.27           0.32         99 5.04       4.93       0.10 
11          5.31 5.43          -0.12         11 5.31       5.10       0.20 
4          4.54 4.03            0.51a         17 5.13       5.39      -0.25 
99          5.04 5.08          -0.04         46 5.01       4.97       0.03 
 
ENT2 
 
Compound   Actual    Predicted       CoMFA          Compound   Actual     Predicted        CoMSIA 
number pKi    CoMFA pKi      Residuals         number         pKi       CoMSIA pKi     Residuals 
 
41          5.02    5.20           -0.18            4  4.55           4.37       0.17 
56          4.38    4.68  -0.30             12  5.14        4.78       0.35 
4          4.55    4.90  -0.35            100  5.31        5.27       0.03 
14          4.85    5.22  -0.37             55  4.88           4.47       0.41 
 
aThe residual values greater than 0.5 is responsible for the low predictivity of the respective models. 
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Table 4.6: Residuals of predictions of external test set by CoMFA and CoMSIA models for hENT1 and hENT2 inhibition 
   
            ENT1 
   
Compound   Actual    Predicted       CoMFA       Compound   Actual     Predicted        CoMSIA 
number pKi    CoMFA pKi      Residuals      number         pKi     CoMSIA pKi     Residuals 
 
101          6.01  5.90               0.11         101 6.01       6.40       -0.38 
102          5.71  5.48               0.22         102 5.71       5.35        0.35 
104          5.56  5.54               0.02         103 5.56       5.42        0.13 
105          5.29  5.22               0.06         105 5.29       5.39       -0.09 
113          5.63  5.56               0.06              113 5.63       5.46         0.16 
                                        114                5.56         5.32               0.24              114     5.56            5.35             0.20 
115               5.38         5.01               0.36         115 5.38           5.22        0.15 
 
ENT2 
 
Compound   Actual    Predicted       CoMFA            Compound   Actual     Predicted       CoMSIA 
    Number       pKi       CoMFA pKi      Residuals            number     pKi     CoMSIA pKi     Residuals 
    
                                    101          5.11    5.14             -0.02              101       5.11           5.33       -0.21     
                                    102          4.94    5.01             -0.07              102      4.94 5.05       -0.10 
                                        103           5.02    5.18             -0.15              103      5.02 5.38       -0.35 
                                        104           4.83    4.17              0.65a              105      4.83            4.78        0.04 
                                        113           5.28    5.23              0.04              113      5.28 5.27        0.01 
                                        114           5.24           5.23             0.01              114      5.24 5.45       -0.21 
                                        115          5.16           5.11             0.05              115      5.16 5.16       -0.18 
 
aThe residual values greater than 0.5 is responsible for the low predictivity of the respective models. 
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Table 4.7: R2 predictivity of the internal and external test sets by CoMFA 
and CoMSIA models for hENT1 and hENT2 inhibition 
 
  hENT1 hENT2 
  CoMFA CoMSIA CoMFA CoMSIA 
Internal 0.75 0.81 0.91 0.82 R2predictivity for 
Test set   
External 0.81 0.67 0.63 0.65 
 
R2 predictivity =  Correlation coefficient for predictive ability 
 
 
 
      (A)                      (B) 
 
Figure 4.10:  Predicted vs actual PKi graphs for external test set for hENT1  
                               inhibition (A) CoMFA and (B) CoMSIA      
 
 
(A)             (B) 
 
Figure 4.11:  Predicted vs actual PKi graphs for external test set for hENT2  
                               inhibition (A) CoMFA and (B) CoMSIA        
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          (A)        (B)             (C) 
 
Figure 4.12:  PLS contours from CoMFA steric and electrostatic (A), CoMSIA steric and electrostatic (B) and 
                CoMSIA hydrophobic and hydrogen bond donor and acceptor (C) descriptors for hENT1  
                 transporter inhibitors 
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                                      (A)         (B)                                                                      (C) 
                                                                    
Figure 4.13:  PLS contours from CoMFA steric and electrostatic (A), CoMSIA steric and electrostatic (B) and 
                CoMSIA hydrophobic and hydrogen bond donor and acceptor (C) descriptors for hENT2  
                 transporter inhibitors 
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magenta and red contours identify favorable and unfavorable positions for hydrogen bond 
acceptors, respectively. 
 
 
4.3.5.1  PLS Contour Interpretation for ENT1 CoMFA 
 
The extended yellow contour surrounding the 4’-position suggests that groups 
large groups are not tolerated at this region.  The green contours near the 5’-position and 
between positions 6 and 7 indicate room for bulky groups. There is also a large yellow 
contour near the 3-position, marking a sterically unfavorable region. Two small blue 
contours at 3- and in between 2’- and 3’- positions show a possible site for occupancy by 
electropositive groups. Red contours at the 5-position and near the 3’-position suggest 
favourable regions for electronegative substituents (Figure 4.12A). 
 
 
4.3.5.2  PLS Contour Interpretation for ENT1 CoMSIA 
  
A green contour surrounded by a large yellow one at 3’-, 4’-, and 5’-positions 
suggest that methoxy is an optimum group for inhibitory activity and groups larger than  
that are not  tolerated. A large red contour occupying 4’-position indicates that an 
electronegative group is favored there. Positions 3’ and 6 blue contours indicate 
electropositively favored regions (Figure 4.12B). 
  
A large yellow contour at the 3- and 4- positions indicates a strong positive 
contribution by a hydrophobic group. The white contour near positions 4’- and 5’- shows 
that this part of the molecule disfavors hydrophobic groups. A cyan contour near the 2’-, 
5-, 6-, and 7- positions, and a magenta contour near the 7- and 1- position oxygens depict 
regions favoring H-bond donor and H-bond acceptor substituents, respectively. The red 
and purple contours near positions 1’ and 6’ and between positions 7 and 8, respectively, 
denote parts of the molecule that neither favor H-bond donor nor H-bond acceptor 
groups, respectively (Figure 4.12C). 
 
 
4.3.5.3  PLS Contour Interpretation for ENT2 CoMFA 
 
A green contour near the 3’- and 4’- positions of the 2-phenyl ring indicates that 
the positions are favorable to sterically bulky groups. Four distinct red contours occur 
near positions 5, 6, 7 and 8, showing that electronegative groups are favored. Blue 
contours at position 4 and over the entire 2-phenyl ring, indicate that electropositive 
groups are favored in that region. Positions 1 and 3’ do not tolerate bulky groups (Figure 
4.13A). 
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4.3.5.4  PLS Contour Interpretation for ENT2 CoMSIA 
 
A red contour at the 3’-position indicates an area that fovors electronegative 
groups. A large green contour on the 2-phenyl ring and a yellow one near position 3 
indicate sterically favored and disfavored regions, respectively. A large blue contour 
occupying half of the 2-phenyl ring at positions 1’, 5’ and 6’ suggests positions which 
favor electropositive substituents (Figure 4.13B).  
 
The yellow contour shielding positions 2 and 3 signifies favorable positions for 
hydrophobic groups. A hydrophobically unfavorable region around positions 3’, 4’ and 5’ 
is indicated by a white contour, one of which also appears between the 6- and 7- 
positions. A cyan contour at the 7-position shows a region that favors H-bond donors. A 
purple contour near position 1 indicates no room for a H-bond acceptor. A magenta 
contour occuring near positions 3 and 4 predicts favorable sites for H-bond acceptors 
(Figure 4.13C). 
 
 To put the significance of the PLS contour maps (isopleths) for equilibrative 
nucleoside transporters in general terms, for both ENT1 and ENT2, (i) substitution at 
positions 3’, 4’ and 5’ of the 2-phenyl ring with methoxy groups increases activity, (ii) 
position 7 favors H-bond donor groups in both transporters but in the case of ENT1, 
position 7 is also suitable for H–bond acceptors and (iii) CoMSIA contours of both ENTs 
suggest that position 3 can tolerate hydrophobic substituents very well and that the meta 
and para positions of the 2-phenyl ring should not be substituted with group bulkier than 
a methoxy group. With regard to differences between the two transporters, the flavone 4-
position prefers electronegative substituents for ENT1inhibition, whereas electropositive 
or H-bond acceptor groups are preferred for ENT2 inhibition as seen from CoMFA and 
CoMSIA contours. 
 
 
4.4  Activity Prediction of In silico Designed Compounds Using 3D-QSAR    
       Models for hENT 
 
The 3D-QSAR models were used to predict the activity of in silico designed 
molecules, before testing them to have an idea of how active the compounds will be with 
a particular structural modification. Since all the models obtained have been validated 
with both internal and external test sets, these models were used to predict the activities 
for designed molecules listed in Table 4.8. Looking at Table 4.8, it can be seen that some 
of the designed molecules are predicted to be more or equally active on specified 
nucleoside transporters. Comparing the predicted activities with already tested 
compounds with high ENT1 inhibitory activity, i.e., compound 16 (pKi = 5.9897), 
compound 95 (pKi = 5.6494) and compound 100 (pKi = 6.8794), the compounds whose 
activities have been highlighted (Pred 14, Pred 25, Pred 26, Pred 28, Pred 29, Pred 31, 
Pred 32, Pred 34, Pred 37, Pred 43 and Pred 46) potentially serve as new lead 
compounds. Similarly, designed compounds designated as Pred 25, Pred 37 and Pred 43 
were compared with flavones with high activity such as compound 35 (pKi = 5.7523) and 
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Table 4.8: Predicted activities for in silico designed compounds 
 
 
 
 
 
 
 
Compound X R2 R3 Y R5 R6 R7 R8 hENT1 
pKi (µM) 
hENT2 
pKi   (µM) 
         CoMFA CoMSIA CoMFA CoMSIA 
             
Pred 1 O 3-hydroxyphenyl NH2 C=O H H OH OH 4.9667 4.4316 4.6229 4.9167 
Pred 2 O 3-hydroxyphenyl CN C=O H H OH OH 5.1387 4.7842 4.7141 4.8779 
Pred 3 O 3-hydroxyphenyl H C=O H H OH Acetyl 5.4279 5.2625 4.7352 5.0758 
Pred 4 O 3-hydroxyphenyl H C=O H H OH N3 5.4430 5.1467 4.5908 5.0876 
Pred 5 O 3-hydroxyphenyl H C=O H H OH Br 5.5202 5.0942 4.5894 4.9482 
Pred 6 O 3-hydroxyphenyl H C=O H H OH Cl 5.5435 5.0951 4.6194 5.0499 
Pred 7 O 3-hydroxyphenyl H C=O H H OH CN 5.5743 5.1164 4.6451 5.1280 
Pred 8 O 3-hydroxyphenyl H C=O H H OH F  5.5001 5.1182 4.7125 5.0579 
Pred 9 O 3-hydroxyphenyl H C=O H H OH Formyl 5.4590 5.1034 4.6204 5.0973 
Pred 10 O 3-hydroxyphenyl H C=O H H OH I 5.5002 5.1064 4.5704 4.8531 
Pred 11 O 3-hydroxyphenyl H C=O H H OH NO2 5.5812 5.2895 4.7178 5.2978 
Pred 12 O 3-hydroxyphenyl H CH2 H H OH OH 4.8592 4.7553 4.7470 4.8403 
Pred 13 O 3-hydroxyphenyl H CH2 H CH3 OH OH 5.0886 4.7025 4.7809 4.8471 
Pred 14 O 3-hydroxyphenyl H C=O H Tetrahydro 
isoquinolino 
H 5.8309 4.4444 4.6323 4.8206 
Pred 15 O 3-hydroxyphenyl NH2 CH2 H H OH OH 4.4106 4.2022 4.7928 4.7836 
Pred 16 O 3-hydroxyphenyl H C=O H H NH2 OH 5.4354 4.6931 4.6446 5.0729 
Pred 17 O 3-hydroxyphenyl H CH2 H OCH3 OH OH 4.8773 4.6013 4.9241 5.1276 
Pred 18 O 3-hydroxyphenyl NH2 CH2 H CN OH OH 4.5074 4.1678 5.0637 5.1274 
Pred 19 O 3-hydroxyphenyl NH2 CH2 H CN OH NO2 4.4495 4.4736 5.1039 5.3695 
Pred 20 O Tetrazoyl  NH2 CH2 H CN OH NO2 4.2530 4.3421 5.2108 5.1041 
Pred 21 O 3-hydroxyphenyl H 3 membered B 
ring 
H H OH OH 4.5342 4.6524 4.7528 4.9934 
Y
X
A B
R8
R7
R6
R5
R3
R2
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Table 4.8: (continued) 
 
Compound X R2 R3 Y R5 R6 R7 R8 hENT1 
pKi (µM) 
hENT2 
pKi  (µM) 
         CoMFA CoMSIA CoMFA CoMSIA 
             
Pred 22 NH 3-hydroxyphenyl H 3 membered B 
ring 
H H OH OH 4.6021 4.8101 4.8324 4.9177 
Pred 23 NH 3-hydroxyphenyl H C=O  H H OH OH 5.0512 5.1034 4.8772 4.9778 
Pred 24 O 3-hydroxyphenyl N C=O  H H OH OH 4.9682 4.6162 4.6105 5.0451 
Pred 25 CH2 3,4,5-trimethoxyphenyl OH CH2 H H OH H 5.4600 5.9839 5.5281 5.3388 
Pred 26 CH2 3,4,5-trimethoxyphenyl OH C=O H H OH H 5.4379 5.7053 5.3607 5.3246 
Pred 27 CH2 3,4,5-trimethoxyphenyl OH CH2 H H OH H 4.9457 5.5269 5.4529 5.1983 
Pred 28 NH 3,4,5-trimethoxyphenyl OH C=O H H OH H 5.4361 5.7499 5.2474 5.1903 
Pred 29 NH 3,4,5-trimethoxyphenyl NH2 C=O H H OH H 5.5229 5.7347 5.2428 5.2174 
Pred 30 O 2-NH2,3,4,5-
trimethoxyphenyl 
OH C=O H H OH H 5.3903 5.6328 5.0574 5.1852 
Pred 31 O 2-OH,3,4,5-
trimethoxyphenyl 
OH C=O H H OH H 5.3475 5.7214 5.0870 5.2855 
Pred 32 O 3,4,5-trimethoxyphenyl OCH3 C=O H H OH H 5.3662 6.1082 4.9755 4.9879 
Pred 33 O 3,4,5-trimethoxyphenyl OH CH2 H H OH H 4.9818 5.3326 5.3137 5.3486 
Pred 34 O 3,4,5-trimethoxyphenyl OH C=O OH H OH H 5.4954 5.6471 5.1075 5.3724 
Pred 35 O 3,4,5-trimethoxyphenyl OH C=O H CN OH H 5.5242 5.5786 5.2953 5.4462 
Pred 36 O 3,4,5-trimethoxyphenyl OH C=O H NH2 OH H 5.5806 5.6177 5.0666 5.5122 
Pred 37 O 3,4,5-trimethoxyphenyl OH C=O H OH OH H 5.4493 5.6917 5.1946 5.5770 
Pred 38 O 3,4,5-trimethoxyphenyl OH C=O H H CN H 5.2615 5.6259 5.1275 5.2233 
Pred 39 O 3,4,5-trimethoxyphenyl OH C=O H H CN NH2 5.3981 5.3858 5.0530 5.0679 
Pred 40 O 3,4,5-trimethoxyphenyl OH C=O H H SH H 5.3780 5.3874 5.0659 5.0677 
Pred 41 O 3,4,5-trimethoxyphenyl OH C=O H H N3 H 5.2917 5.4933 5.1282 5.1297 
Pred 42 O 3,4,5-trimethoxyphenyl OH C=O H H NH2 H 4.8180 5.2448 5.1041 5.4818 
Pred 43 O 3,4,5-trimethoxyphenyl OH C=O H H NO2 H 4.8579 5.7248 5.0449 5.7607 
Pred 44 O 3,4,5-trimethoxyphenyl H C=O H H OH H 5.8899 6.0929 5.2056 5.4481 
Pred 45 O 3,4,5-triethoxyphenyl OH C=O H H OH H 4.8010 5.4859 5.1398 5.4732 
Pred 46 CH2 3,4,5-trimethoxyphenyl OCH3 CH2 OCH3 OCH3 OCH3 H 3.8673 4.9775 5.0926 4.7774 
Pred 47 O 3,4-methylenedioxy-5-
methoxy phenyl 
OH C=O H H OH H 4.4506 4.6531 5.1749 5.2832 
Pred 48 O 3,4,5-trimethoxyphenyl OCH3 C=O OCH3 OCH3 OCH3 H 4.6644 4.9352 5.3064 5.0092 
 76
Table 4.8: (continued) 
 
Compound X R2 R3 Y R5 R6 R7 R8 hENT1 
pKi (µM) 
hENT2 
pKi  (µM) 
         CoMFA CoMSIA CoMFA CoMSIA 
             
Pred 49 O 3,4,5-trimethoxyphenyl H C=O OCH3 OCH3 OCH3 H 3.8986 4.7961 5.2973 5.2324 
Pred 50  O 3,4,5-trimethoxyphenyl OH C=O OCH3 OCH3 OCH3 H 4.5602 4.7015 5.2820 5.1549 
Pred 51 O 3,4,5-trimethoxyphenyl H C=O H H OCH3 OCH3 5.9877 6.1593 5.1374 5.2996 
Compound 
XI 
O 3,4,5-trimethoxyphenyl ------ ------ H H OCH3 OCH3 4.5792 5.6280 5.4714 5.2555 
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compound 96 (pKi = 5.7523) for ENT2 inhibition, and can be evaluated for identification 
of new ENT2 inhibitor leads. Pred 51 has the highest predicted activity. Only one of 
these compounds, Pred 34 was found to be commercially available. Hence, synthesis of 
rest of these novel compounds and biological evaluation of all of them are the major 
goals for future work (Figure 4.14). Also, compound XI (mentioned in section 4.6) was 
predicted in silico, but predicted activity values may not be reliable due to significant 
difference in the structure of compound XI and the series of flavones used to derive the 
3D-QSAR models. 
 
 
4.5  Evaluation of Related Analogs 
 
Based on the general SAR of flavones tested for the above analyses, some more 
flavones and analogs were further tested on both ENT1 and ENT2. Table 4.9 shows the 
list of those extra set of compounds with their IC50 values. The structures of these 
compounds are shown in Figure 4.15. The screening graphs and IC50 curves are shown in 
Figure 4.16. From these results, it can be clearly seen that compound 101 is highly active 
against ENT1 whereas, compound 111 is selectively potent against ENT2. 
 
 
4.6  Synthesis and Testing of a New Lead as an Equilibrative Nucleoside   
       Transporter Specific Inhibitor 
 
An analysis of SAR for ENT1 and ENT2 inhibition showed that the compounds 
with methoxy substitution at positions 7, 8, 3’, 4’ and 5’, consistently showed high 
potency (compounds 3, 16, 22, 35). This information was used to design compound XI, 
which is less constrained compared to the flavones to find out minimum structural 
features required for ENT inhibitory activity (Figure 4.17). Figure 4.18 shows the 
synthetic route followed to prepare compound XI; but this reaction resulted in C-
alkylation instead of O-alkylation, thus, giving compounds XII and XIII. Due to 
structural isomerism (same molecular weight) and same Rf values, the mixture could not 
be separated into two different compounds.  
 
Thus, the mixture of compounds XII and XIII was evaluated at 10 µM 
concentration against hENT1, hENT2 and hCNT3 transporter cell-lines to find out the 
effect of these novel molecules. Interestingly, the mixture showed substantial inhibitory 
activity against ENT1, but low activity against ENT2, and no significant activity against 
hCNT3. This further provides insight into the differences among ENT1, ENT2 and CNT3 
inhibitor pharmacophores.  Figure 4.19 shows the comparison graph. 
 
 
4.7  Discussion 
 
All flavone analogs screened against concentrative nucleoside transporters were 
tested against ENT1 and ENT2 using a [3H]-uridine uptake assay. NBMPR and 
dipyridamole were used as positive controls with respect to which the biological activities 
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Figure 4.14: In silico compounds with high inhibitory activity against ENT1 and 
                         ENT2
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Table 4.9: Biological activity data of compounds 101 to 115ab 
 
Compound 
No. 
Name hENT1 
IC50 (µM) 
hENT2 
IC50 (µM) 
    
101 3’-benzyloxy-5,6,7,4’-tetramethoxy flavone 0.96 7.62 
102 5,6,7,3’,4’-pentamethoxyflavone (Sinensetin) 1.93 11.46 
104 3’,4’,5,6,7,8-hexamethoxyflavone (Nobiletin) 2.72 9.43 
105 6,7,3’,4’-tetramethoxyflavone 5.10 14.77 
106 3,7-dihydroxy-3’,4’-dimethoxyflavone --- --- 
107 3-Amino-1-pyridine-4-yl-1H-benzo(F)chromene-2-carbonitrile 2.10 5.02 
108 4H-1-Benzopyran-3-carbonitrile-2-amino-7-hydroxy-4-phenyl 8.41 4.37 
109 4H-1-Benzopyran-3-carbonitrile-2-amino-7-hydroxy-4-(3-nitrophenyl)- 8.59 3.49 
110 Acetamide, N-[4-(3-carbonitrile-2-amino-7-hydroxy-4H-1-benzopyran-4-yl) phenyl] 7.82 6.08 
111 4H-1-Benzopyran-3-carbonitrile-2-amino-7-hydroxy-4-(3-cyclohexen-1-yl) 9.38 1.90 
112 4H-1-Benzopyran-3-carbonitrile-2-amino-4-phenyl-7-(phenylamino) 13.56 4.73 
113 4H-1-Benzopyran-4-one, 6-hydroxy-2-(3,4,5-trimethoxyphenyl)- 2.34 5.20 
114 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-3-methoxy- 2.74 5.70 
115 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-6-methoxy- 4.11 6.77 
 
aTested as inhibitors of [3H]-uridine uptake by hENT1 or hENT2 
 
bThe structures of these compounds are shown in Figure 4.15. 
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Figure 4.15:  Structures of compounds 101 to 115 
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Figure 4.16:  (A) Screening at 10 μM on ENT1 and ENT2, (B) IC50 curves for ENT1 
             and (C) IC50 curves for ENT2  
(A) 
(B) 
(C) 
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Figure 4.17:  Structural similarity between active flavones and compound XI 
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Figure 4.18:  Synthetic scheme 
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Figure 4.19:  Comparison graph of mixture of compound XII and XIII screening  
 
 
of compounds in the study were compared. None of the flavones tested was found to be 
as potent as the standards against ENTs. From the SAR established from the available 
biological activity data, the following points highlight some of the important features that 
determine the inhibitory activity of flavones.ENT1 transporter shows a higher sensitivity 
to flavones than ENT2, since a greater number of flavones are active against ENT1. For 
ENT1 inhibition, compound 95 (IC50 of 2.24 µM) is the most specific inhibitor. 
Compound 100 (IC50 of 0.13 µM) is the most potent ENT1 inhibitor and belongs to the 
quinoxaline class. A 3,7-dihydroxy substitution with 3’, 4’, 5’-trimethoxy substitution 
was a favorable structural feature for ENT1 inhibition. The most potent flavone is 
compound 16, with an IC50 of 1.02 µM.  Also, compound 66 (SI = 15) is significantly 
selective for ENT1 inhibition. Compounds 16 (SI = 2.75), 19 (SI = 3.34), 22 (SI = 4.72), 
51 (SI = 4.66), 56 (SI = 7.34), and 93 (SI = 1.82) also exhibit low selectivity for ENT1 
inhibition. Comparing compound 66 and 70, it is clear that the 7,8-furano- substituent is 
worst for ENT1 inhibition compared to 7,8-naphtho- compound. Also, naphthoflavones 
with only 2’-OH or 4’-OH are not active against ENT1 (compound 64 and 68), but need 
to be un-substituted or have 3’,4’-dihydroxy, 3’-OH or 4’-methoxy substitution to exhibit 
inhibitory activity against ENT1 (compounds 61, 63, 66, 71). The information obtained 
from compounds that are exclusively active against ENT1, i.e. flavone compounds 6, 8, 
52, 54, 57, 61, and 71, suggests that a 2-phenyl group with 3- and 4- positions occupied 
by hydrophobic and H-bond acceptor type substituents, and 7- and 8- positions 
substituted with methoxy groups or hydroxyl groups are essential structural features. 
Active coumarin compounds 89, 91, 92, and 95 suggest that the 3-position phenyl ring 
enhances activity in this series, since compounds 91 and 95 are more active than 92. 
Also, a comparison of 91 and 95 shows the favorability of 4- and 5-OH groups to 
inhibitory activity. Isoflavones 78, 79, 83, 97, and 99, which are active against only 
ENT1, strongly suggest that bulk is well tolerated at position 3 by the ENT1 transporter. 
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All the chalcones are active against ENT1, with the most active chalcone being 
compound 44 (IC50 of 3.64 µM). Compound 101 in the later studied series is the best 
ENT1 inhibitor with an IC50 value of 0.96 µM, which suggests that groups with more 
bulk than –OCH3 group are well tolerated at the 3’-position. Also, 3’,4’,6,7-tetramethoxy 
substitution  is favorable for ENT1 inhibition (compounds 101,102, 104, 105).  
 
The most active inhibitors of ENT2 are compound 35 (a flavone, IC50 of 1.77 µM) 
and compound 96 (4-pyridinyl-4H-chromene derivative, IC50 of 1.77 µM). These two 
compounds are chemically different structures. They may or may not bind at the same 
site. Compound 3 is another flavone that is a potent ENT2 inhibitor (IC50 of 1.81 µM). 
Compound 30 is the most selective (SI = 9.11), though it is not the potent one. Other 
compounds with some selectivity for ENT2 inhibition are: 3 (SI = 7.77), 5 (SI = 3.33), 15 
(SI = 1.96), 23 (SI = 7.77), 27 (SI = 6.07), 34 (SI = 3.56), 41 (SI = 2), 53 (SI = 2.77), 
and 72 (SI = 2.18). Isoflavones are less active than flavones as inhibitors of ENT2 
(compare compounds 78, 79, 80, 81, 82, 83, 97 and 99). Compound 45 belonging to the 
chalcone class, is 6 times more selective towards ENT2 compared to ENT1. Coumarins 
are not good inhibitors of ENT2 (see compounds 91 and 93). Compound 111 (IC50 of 1.90 
µM) is the most active ENT2 inhibitor in the series 101 to 115. The results from this 
analysis, suggest that 2-amino-3-cyano- substitution is a fairly good structural feature for 
ENT2 inhibition compared to ENT1, and may be exploited to obtain selective ENT2 
inhibitors, which are currently lacking. 
 
Comparing the biological activity data of equilibrative nucleoside transporters vs 
concentrative nucleoside transporter inhibition, it appears that the active site of ENTs is 
more hydrophobic relative to CNTs. The most sensitive nucleoside transporter among the 
five is CNT3. Compound 49, which is the most active against both CNT1 and CNT2, is 
inactive against the ENTs. Also, compounds 39 (IC50 of  0.57 µM) and 50 (IC50 of  0.68 
µM), which show very potent inhibition against CNT3, are not significantly active 
against ENTs.  
 
QSAR studies have been successfully applied for modeling biological activities of 
the flavones tested. In this work, we carried out 3D-QSAR studies for establishing 
correlations between structural properties of 95 flavones and analogous compounds such 
as coumarins and a quinoxaline and their inhibitory activities against ENT1 and ENT2. 3-
D QSAR analysis was performed using CoMFA and CoMSIA methods.  
    
The models generated show correlation coefficients (r2) of 0.937 and 0.928 
(ENT1), and 0.870 and 0.957 (ENT2) with cross-validated r2 (q2) of 0.585 and 0.523 
(ENT1), and 0.510 and 0.565 (ENT2), respectively for CoMFA and CoMSIA. Taking 
into consideration the contributions made by different descriptors, electrostatic 
descriptors contributed the most, followed by the hydrogen bond donor descriptor. These 
two main descriptors were followed by H-bond acceptor and hydrophobic properties in 
ENT1 and ENT2 models, respectively.  
 
The standard deviation (s), Fischer ratio (F) and the statistical results for the 
validation exercises performed to prove the robustness of these models demonstrated a  
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high degree of reliability of the models. The q2 and r2 values obtained from group cross-
validation and bootstrapping respectively, are not significantly different from the original 
values. The negative q2 values obtained for all models using randomized activity data 
indicate that correlations of the models were not due to chance. The predictive ability of 
the models was validated using an internal and external test set of compounds which had 
not been included in the training sets of compounds. The predictive r2 values for these 
ligand-based CoMFA and CoMSIA models were significantly high in all the models in 
the case of the internal set, but in the case of the external test set, only the CoMFA model 
of ENT1 afforded good predictions (Table 4.8).  
 
The models derived from 3D-QSAR were used to predict the activities of in silico 
designed molecules and some of the highly predicted molecules (Pred 14, Pred 25, Pred 
26, Pred 28, Pred 29, Pred 31, Pred 32, Pred 34, Pred 37, Pred 43, Pred 44 and Pred 
51 for ENT1, and Pred 25, Pred 37 and Pred 43 for ENT2) can be obtained and assayed 
to check the validity of the models in a practical sense and in an attempt to search for 
more potent compounds. From the results of the SAR and QSAR studies, a novel lead 
compound, XI was designed but the synthesis failed to yield the compound, but rather 
produced the mixture of compounds XII and XIII . A different synthetic route will have 
to be used to obtain compound, XI. The mixture of compounds XII and XIII will have to 
be separated to determine which one is more potent. 
 
  
4.8  Conclusion 
 
In the study, ninety five flavonoids and related compounds (Table 4.1) were 
studied by qualitative SAR and 3D-QSAR analyses. CoMFA and CoMSIA 3D-QSAR 
models provided insights regarding how different functional groups affect potency and 
transporter selectivity. The statistically validated models were used for in silico 
prediction of designed compounds which identified potential novel inhibitors, which are 
still to be obtained and biologically evaluated. Considering the combined activity of 
compounds XII and XIII for ENT1, some more analogs can be synthesized and their 
inhibitory activities can be examined. Thus, the work undertaken, including the biological 
evaluation, the analysis of 2-D and 3-D structure activity relationships and synthesis of 
compounds XII and XIII can help to better understand the structural determinants of 
equilibrative nucleoside transporter inhibition and rational design of new, specific and 
more effective inhibitors, but the obtained information may not be applied to structurally 
more diverse flavones. This work has also identified the first hENT2-selective inhibitors 
(compound 3, 35 and 96) relative to ENT1. In  comparing the activity data of ENTs with 
CNTs (see Chapter 3), one distinct observation about the active sites is that the binding 
site for flavones at ENTs is more hydrophobic than that at CNTs. 
 
 
4.9  Experimental Section: Chemistry 
 
 Thin- layer chromatography (TLC) was performed on silica gel plates (Analtech). 
Compounds were visualized by UV light (254 and 365 nm). 1D NMR spectra were 
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recorded on a Varian Inova 500 MHz NMR instrument using (CD3)2SO as solvent and 
tetramethylsilane (TMS) as an internal standard. Flash column chromatography was 
performed on Fischer silica gel (170-400 mesh). Mass spectra were obtained on Bruker 
HP ESQUARE Ion Trap LC/MS (n) system. All solvents and reagents were purchased 
from Aldrich and used without further purification unless otherwise indicated. 
 
 
4.9.1  Reaction Procedure 
 
To a solution of potassium hydroxide, (100 mg, 1.6 mmol) in 12 mL water, 3, 4,5-
trimethoxy benzyl chloride, IX (500 mg, 3.2 mmol), 2,3-dimethoxy phenol, X (690 mg, 
3.2 mmol) and the  ionic catalyst 1-ethyl-3-methylimidazolium tetrafluoroborate (0.4mL,  
0.3 mmol) were added. The mixture was stirred at room temperature for 5 hours. The 
mixture of compounds XII and XIII (721 mg) was isolated from other impurities by 
extraction using ethyl acetate and purification by column chromatography with a solvent 
system containing n-hexane/ethyl acetate (8:2). The NMR and mass spectra of mixture of 
compounds XII and XII are reported in Figure A.1 and A.2 in the appendix section, 
respectively. 
 
 
4.9.2  Mixture of Compounds XII and XIII 
 Yield 60 %; light yellow semisolid; (ESI, Pos) m/z 357.2 [(M + 23)] +; 1H NMR 
(500 MHz, DMSO) 6.707 (H, dd, J = 8.5 Hz, ArH ), 6.539 (2H, d, J = 9.5 Hz, ArH), 
6.479 (H, s, ArH), 6.429 (1H, d, J = 8.5 Hz, ArH), 3.743 (6H, s, 2 OCH3), 3.718 (9H, s, 3 
OCH3), 3.679 (2H, s, methylene H). 
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Chapter 5: Pharmacophore Mapping of Flavone Derivatives for  
hCNT3 Inhibition 
 
 
5.1  Introduction 
 
 Human concentrative nucleoside transporters are being studied extensively by 
researchers to find out the exact features of the active sites of these 13 transmembrane 
domain proteins.16-20 In the meantime, to identify new potent inhibitors, most of the 
methods rely on ligand-based drug design and one of such approaches is ligand-based 
pharmacophore mapping. The pharmacophore concept is based on the kinds of 
interaction observed in molecular recognition, i.e., hydrogen bonding, charge, aromatic, 
and hydrophobic interactions and their arrangements in 3D space. Pharmacophores 
generated can be used as queries in 3D database searching to identify new structural 
classes of potential lead compounds, and can also serve as templates for generating 
alignments for 3D-QSAR studies. Two types of pharmacophore hypothesis are well 
established: receptor-based and receptor-independent pharmacophores. Receptor based 
pharmacophore mapping cannot be performed in this case since X-ray crystal structures 
are still not available for human concentrative nucleoside transporters. Hence, the most 
suitable choice is receptor-independent and ligand-dependent pharmacophore 
mapping.149-151 Consequently, the present work was undertaken to study the flavone  
scaffold with a view to deduce the active pharmacophore based on a receptor-
independent hypothesis, using the PHASE152 program (Schrodinger Inc.), that can 
eventually aid in comprehending the effects of different compounds containing this unit. 
 
  
5.2  Materials and Methods 
 
 In the present study, 62 compounds of a series of flavone analogs were 
considered. The general structure and activity data of flavones used in the study are 
presented in chapter 3, Table 3.1. The steps involved in the pharmacophore mapping 
undertaken are: 1) preparation of ligands, 2) creation of the pharmacophoric sites, 3) 
finding common pharmacophores, 4) scoring hypotheses and 5) deriving 3D-QSAR 
models. The compounds used in the pharmacophore mapping have the following general 
structure (Figure 5.1), and are listed in Table 5.1 with the activity and number of 
conformations generated. 
 
 
 
 
 
 
 
 
 
Figure 5.1:  General structure of compounds used in the study 
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Table 5.1: Compounds used in pharmacophore mapping 
 
   Compound   Activity Pharm Set  No. of conformationsa 
    No.      pKi 
 
     50   6.237     Active   7 
     84   6.056     Active   15 
     13   5.863     Active   4 
     83   5.591     Active   7    
     34   5.443     Active   20 
     12   5.395     Active   5 
     72   5.253     Active   11 
     49   5.216     Active   7 
     74   5.201     Active   3 
     51   5.145     Active   9 
     11   5.124     Active   5 
     57   5.093     Active   15 
       5   5.030     Active   4 
       3   5.019     Active   7      
     85      4.991     Active   9     
     62   4.942     Active   5 
     63   4.905     Active   4 
     52   4.874     Inactive   4 
     71   4.871     Inactive   2 
     33   4.863     Inactive   11 
     66   4.857     Inactive   3 
     67   4.842     Inactive   3 
     10   4.815     Inactive   9 
     23   4.815     Inactive   8 
     42   4.815     Inactive   7 
     70   4.766     Inactive   3 
     60   4.763     Inactive   2 
       8   4.724     Inactive   5 
     80   4.712     Inactive   4 
     27   4.711     Inactive   6 
     55   4.658     Inactive   3 
     75   4.656     Inactive   2 
     15   4.652     Inactive   4 
     81   4.652     Inactive   4 
     79   4.639     Inactive   7 
     17   4.637     Inactive   7 
     40   4.637     Inactive   3 
     31   4.622     Inactive   9 
     48   4.597     Inactive   5 
     64   4.588     Inactive   5 
     59   4.571     Inactive   3 
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Table 5.1: (continued) 
 
 Compound   Activity Pharm Set  No. of conformations 
     No.      pKi 
 
     78   4.570     Inactive   7 
     32   4.565     Inactive   7 
     61   4.562     Inactive   2 
     54   4.560     Inactive   5 
     65   4.554     Inactive   5 
     16   4.536     Inactive   8 
     4   4.536     Inactive   4 
     77   4.531     Inactive   2 
     56   4.521     Inactive   3 
     68   4.475     Inactive   3 
     69   4.448     Inactive   2 
     58   4.432     Inactive   3 
     35   4.374     Inactive   9 
     2   4.326     Inactive   5 
     82   4.325     Inactive   4 
     30   4.321     Inactive   6 
     19   4.261     Inactive   3 
     9   4.216     Inactive   4 
     14   4.202     Inactive   4 
     6   4.055     Inactive   4 
     22   3.825     Inactive   2 
 
 
aThe more rotatable bonds in a molecule, the more the no. of conformations generated for 
it. This general concept is applicable to the molecules in the study. 
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 5.2.1  Preparation of Ligands 
 
The chalcones and glucoside (compound 43 – 47 and 73) were not included in the 
data set due to differences in structure; and compound 39 was eliminated due to strong 
possibility of the existence of a different binding mode. The conformations of each 
molecule were generated using the OPLS_2005 force field153 with a maximum relative 
energy difference of 10 kcal/mol, distance-dependent dielectric solvation treatment and 
minimum atom deviation of 2 Å. The activity cut off was set to pKi equal to 4.9, above 
which compounds are defined as active and below which the compounds were considered 
as inactive. Hence, the entire data set was divided into 17 actives and 45 inactives. 
 
 
 5.2.2  Creation of Pharmacophoric Sites 
 
After generation of conformations for each ligand in the study, the different 
pharmacophoric sites were generated , using inbuilt parameters for H-bond acceptor (A), 
H-bond donor (D), hydrophobic (H), negative (N) , positive (P) and aromatic (R) 
functional groups present in the molecules. The sites are represented as follow: 
Acceptor= Red sphere with vectors pointing in the direction of possible interaction, 
Donor= Blue sphere with vectors pointing in the direction of possible interaction, 
Hydrophobic= Green sphere and Aromatic= Orange ring at the center of aromatic ring. 
For the given set of molecules, no positive or negative features were generated due to 
their absence. There is an abundance of acceptor and donor sites in almost all molecules. 
Most distinguishing feature between active and inactive sets of molecules is presence of 
hydrophobic sites in inactive ligands with exceptions of two compounds in the active set 
(compounds 63 and 84). Figure 5.2 shows all compounds with the pharmacophoric sites.  
 
 
 5.2.3  Finding a Common Pharmacophore 
 
 To find the common pharmacophore mapping all the active and inactive ligands, 
the number of pharmacophoric site features was varied from 5 through 7. The feature 
frequencies were adjusted to four for acceptor, two for donor, and three for aromatic ring. 
Also the minimum no. of actives to be matched to a common pharmacophore was set to 
at least 12 out of 17 active ligands. Attention was focused on the 7- site pharmacophore 
hypotheses, to derive more specific pharmacophore for CNT3. The two pharmacophores, 
AAAADDR and AAADRRR as marked in bold in Table 5.2 were finally selected for 
generating hypotheses and in all 20 hypotheses of these two combinations were derived 
which were common to most active ligands in the data set. 
 
 
 5.2.4  Scoring Hypotheses 
  
 A scoring procedure is applied to identify the pharmacophore that yields the best 
alignment of the active ligands. The scoring procedure provides a ranking of the different 
hypotheses, allowing the making of rational choices about which hypotheses are most 
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       (A)                  (B)              (C) 
 
Figure 5.2:  (A) All ligands with pharmacophoric sites, (B) active ligand set and (C) inactive ligand set 
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Table 5.2: Pharmacophore generation 
 
 
    No. of          No. of              List of variants                                       No. of                        No. of  
    sites                     variants                                    pharmacophores             common 
                                                                                                                                                      pharmacophore 
 
        5                         11           AAAAD, AAAAR, AAADD,                             1025   10 
                                    AAADR, AAARR, AADDR, 
                                    AADRR, AARRR, ADDRR, 
                                    ADRRR, DDRRR 
 
       6                          9           AAAADD, AAAADR, AAAARR,                247    7 
                                    AAADDR, AAADRR, AAARRR, 
                                    AADDRR, AADRRR, ADDRRR 
 
       7                         6                    AAAADDR, AAAADRR,                    35   2 
                                              AAAARRR, AAADDRR,  
                                  AAADRRR, AADDRRR 
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appropriate for further investigation. In the scoring process, a survival box is built which 
contains a set of very similar pharmacophores culled from conformations of a minimum 
number of active ligands, and certain of these ligands may contribute more than one 
pharmacophore to a box. Each pharmacophore and its associated ligand are treated 
temporarily as a reference in order to assign a score. This means the other non-reference 
pharmacophores in the box are aligned, one-by-one, to the reference pharmacophore, 
using a standard least-squares procedure applied to the corresponding pairs of site points. 
At this stage, the quality of each alignment is measured using up to three terms: (1) the 
root-mean-squared deviation (RMSD) in the site point positions; (2) the average cosine of 
the angles formed by corresponding pairs of vector features (acceptors, donors and 
aromatic rings); and (3) a volume overlay term (Equation 5.1) based on van der Waals 
models of the non-hydrogen atoms in each pair of structures. 
 
                                            Svol(i) = Vcommon(i) / Vtotal(i)                                      (Eq. 5.1) 
 
Vcommon(i) is the common or overlapping volume between ligand i and the 
reference ligand, while Vtotal(i) is the total volume occupied by both ligands. The volume 
term is computed only if the option to score by volume is selected. These two or three 
terms are combined with separate weights to yield a combined alignment score for each 
non-reference pharmacophore that has been aligned to the reference. If a non-reference 
ligand contributes more than one pharmacophore to the box, the pharmacophore yielding 
the best alignment to the reference is selected. The overall multi-ligand alignment score 
for a given reference pharmacophore is the average score from the best set of individual 
alignments.152 
 
  For the current study, 20 hypotheses were selected, each of which contained 7 
pharmacophoric sites. Hypothesis 1 and 11 scored the highest in AAADRRR and 
AAAADDR combinations. Table 5.3 lists the survival scores of each of those hypotheses 
with number of active ligands matched to it. The derived hypotheses are only used to 
obtain ligand alignments. It does not contribute in any way to the QSAR model itself. 
Instead, hypotheses have an association with the model, because they define how ligands 
should be pre-aligned before applying the model. Also, there is no necessary connection 
between the score and the quality of the QSAR models. Figure 5.3 and 5.4 show all of the 
hypotheses with compound 50 co-displayed with them. As seen in the Figure 5.3 
(hypotheses 1 to 10), three acceptors, one donor and three aromatic features cover 
different parts of the molecule to give the common pharmacophore. Similarly, Figure 5.4 
(hypotheses 11 to 20) shows four acceptors, two donors and an aromatic feature 
contributing to generation of the common hypothesis. 
 
 
5.2.5  Building a QSAR Model 
 
 The building of most QSAR modes requires alignment of ligands according to a 
“bioactive conformation”. Sixty two training and test set ligands cannot all be expected to 
match all seven sites in the hypotheses. Some weak inhibitors will be missing one or 
more features contained in the hypothesis. To deal with this possibility, PHASE uses 
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Table 5.3: Scoring results 
 
   No.     Hypotheses    Survival       No. of actives matched 
 
   1    AAADRRR  3.778    12 
   2   AAADRRR  3.756    12 
   3   AAADRRR  3.699    12 
   4   AAADRRR  3.656    11 
   5   AAADRRR  3.608    11 
   6   AAADRRR  3.600    11 
   7   AAADRRR  3.542    11 
   8   AAADRRR  3.297    11 
   9   AAADRRR  3.295    11 
 10   AAADRRR  2.809    12 
 11   AAAADDR  3.490    10   
 12   AAAADDR  3.490    10 
 13   AAAADDR  3.462    10 
 14   AAAADDR  3.366    10  
 15   AAAADDR  3.345    10 
 16   AAAADDR  3.345    10 
 17   AAAADDR  3.038    10 
 18   AAAADDR  2.936    10 
 19   AAAADDR  2.918    10 
 20   AAAADDR  2.918    10 
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 6    7        8    9    10 
 
Figure 5.3:  Hypotheses belonging to pharmacophore AAADRRR 
 
represents selected pharmacophore for QSAR studies 
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 11    12         13   14    15 
 
 
             
 
 
 16    17        18    19    20 
 
Figure 5.4:  Hypotheses belonging to pharmacophore AAAADDR 
 
 
represents selected pharmacophore for QSAR studies 
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partial matching to obtain alignment of inactive ligands in which, if at least three sites are 
matched, a proper alignment is obtained. For each ligand, outside the active set, then 
PHASE searches for matches involving the largest possible number of sites and identifies 
the match that yields the highest fitness score. These alignments can give information 
about which features are important and which are not, especially for actives that are not 
in the training set. PHASE QSAR models are based on partial least-squares (PLS) 
regression, applied to a large set of binary-valued variables that encode whether or not 
ligand atoms or features occupy various cube-shaped elements of space. PHASE can 
generate QSAR models that are atom-based or pharmacophore-based. The independent 
variables in the QSAR model are derived from a regular grid of cubic volume elements 
that span the space occupied by the training set ligands. For our study, after aligning the 
inactive set, all the listed hypotheses were subjected to pharmacophore based QSAR 
model development with a grid spacing of 1 Å and 5 PLS factors and by choosing the test 
set of 10 compounds randomly. Different combinations of compounds to comprise the 
test set were investigated. The results of the QSAR models have been listed in Table 5.4. 
 
 
5.3  Results and Discussion 
 
 As mentioned in section 5.2.4, the high scoring hypothesis does not necessarily 
give a good model; the results reflected this fact. The hypotheses which scored highest in 
category AAADRRR, i.e., hypothesis 1, did not contribute to a better model. Instead, 
hypothesis 10, gave a good QSAR model. For the category AAAADDR, hypothesis 14 
gave a reliable QSAR model.  
 
As seen in Table 5.4, the data set is divided into training and test set, and the 
compounds belonging to the test set were kept constant to compare the results obtained 
for both of the hypotheses. Hypothesis AAAADDR is better in terms of R2 (equal to 
0.6197) which means that the model accounts for 61.97 % of the variance in the observed 
activity data) and Q2 (equal to 0.5196), compared to AAADRRR, but both of them have 
almost the same Pearson-R value which indicates the correlation between the predicted 
and observed activity for the test set. Figure 5.5 shows the alignment of training set and 
test set compounds for both high quality hypotheses AAADRRR and AAAADDR. The 
contributions of different pharmacophore features to the QSAR are shown in Figure 5.6 
for both hypotheses. 
 
All panels of Figure 5.6 contain compound 50 co-displayed with the hypothesis. 
For A, B, and C, the molecule has deflected from the hypothesis, due to a comparatively  
lower fitness ratio with the hypothesis AAADRRR. The red cube shows an unfavorable 
region and the blue one shows favorable regions of the ligand for a particular 
pharmacophoric feature. The QSAR results mapped to the cubes, for both hypotheses 
show that positions 1, 4, and 8 harbor strong concentrations of blue cubes, indicating 
their importance as major contributors to inhibitory activity. Position 7 of the flavone is 
favored for a H-bond donor as well as acceptor, but the donor feature predominates. The 
A and C rings of the flavone (shown in Figure 5.1) have to be aromatic in nature as 
shown by higher number of blue cubes accumulated in those parts of the flavone,  
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Table 5.4: QSAR results 
 
Hypothesis AAADRRR AAAADDR 
Survival rate 2.809 3.366 
No. of compounds in 
training set 
51 52 
No. of compounds in test 
set 
11 10 
Test set compounds 11, 13, 34, 48, 55, 59, 65, 77, 
78, 82, 85 
11, 13, 34, 48, 55, 59, 65, 
77, 82, 85 
PLS factors 5 5 
SD 0.3194 0.2817 
R2 0.5201 0.6197 
F 9.8 15 
P 2.314e - 06 9.998e-09 
RMSE 0.3146 0.3187 
Q2 0.5005 0.5196 
Pearson-R 0.7286 0.7281 
 
SD= Standard deviation of regression, R2= Coefficient of determination, F= Ratio of 
model variance to observed activity variance, P= Significance level of F, RMSE= RMS 
error in the test set prediction, Q2= Parameter directly proportional to R2, Pearson-R= 
Correlation constant for predicted and observed activity for test set. 
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     (A) AAADRRR Training Set                (B) AAADRRR Test Set 
 
 
                                                                       
 
   (C) AAAADDR Training Set            (D) AAAADDR Test Set 
     
Figure 5.5:  Training and test set used for building QSAR models for hypotheses AAADRRR (A, B) and AAAADDR (C, D)
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 (A) Acceptor contribution                                    (B) Donor Contribution    (C) Aromatic Ring Contribution  
 
 
                
 
     (D) Acceptor contribution                                (E) Donor Contribution     (F) Aromatic Ring Contribution  
 
Figure 5.6:  Contribution of sites to pharmacophores AAADRRR (A, B, C) & AAAADDR (D, E, F) 
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whereas ring B does not display that much importance for an aromatic feature as do rings 
A and C.  
 
 
5.4  Pharmacophore Based Database Searching 
 
 Although, docking and scoring have been the most widely employed techniques, 
ligand-based virtual screening has also gained momentum in recent years, and in the 
absence of a crystal structure, it is one of the most widely used computer-aided 
approaches for drug lead discovery. 154-156 As mentioned at the beginning of the chapter, 
the main aim of this study was to derive a reliable pharmacophore model which can be 
applied for QSAR studies and pharmacophore-based database screening to identify hits 
with similar chemical features, which is the next step in the study. For this purpose, two 
methods were followed. One is the use of the PHASE derived pharmacophore models to 
find matches using different databases (Figures 5.7A and 5.7B). The other approach is to 
generate a 3D map of these pharmacophoric features by defining the distances and 
distance tolerance between them (Figures 5.7C and 5.7D) and then using this map as a 
query to perform UNITY database searching. Figures 5.7A and 5.7B contain the two 
pharmacophores that can be used as such for finding matches, and Figures 5.7C and 5.7D 
are the 3D maps of the pharmacophores built in the SYBYL UNITY module. 
 
 
5.5  Summary 
 
 In view of these observations, the present study may have identified some 
important pharmacophores of flavone derivatives for concentrative nucleoside transporter 
type 3 inhibition. 3D-pharmacophore models were generated using a data set of 62 
compounds which was split into training and test sets. The best models consisted of 
important chemical features, and mapped well to the ligands. The fairly good predictive 
abilities of these models are shown by Pearson-R values of 0.7286 and 0.7281 for 
hypothesis AAADRRR and AAAADDR, respectively. The study also supports the notion 
that the presence of three aromatic rings with 7- position donor and 8- position acceptor 
groups is the optimum for activity and can be used as a template pharmacophore for 
virtual screening using various available modeling programs and databases. Additionally, 
the presence of H-bond acceptors at position 1 and 4 contributes favorably to activity.  
 
 Thus, in conclusion, it can be stated that the pharmacophore models derived from 
this study may be used to retrieve inhibitors from databases and hence they could be used 
as a fast tool to assist the discovery of novel hCNT3 inhibitors either at the hit discovery 
(database screening) or lead optimization (activity prediction) stages. 
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                    (A)                         (B) 
 
 
  
                  
                      (C)                                       (D) 
 
Figure 5.7:  PHASE hypotheses (A and B) and UNITY query (C and D) to be used for database searching 
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Appendix: Proton and Mass Spectrum of Compounds XII and XIII 
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Figure A.1: Proton spectrum  
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Figure A.2: ES mass spectrum  
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